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Abstract 
Barrett’s esophagus incidence has been on the rise for the past four decades. Early identification 
of Barrett’s esophagus is essential to preventing the morbidity and mortality associated with 
esophageal adenocarcinoma, a malignancy with an 18% five-year survival rate. With no national 
standard for screening, primary care providers must identify and refer patients who are at high 
risk of Barrett’s esophagus for endoscopic evaluation. This quality improvement project aimed to 
develop a protocol to identify patients at high risk for Barrett’s esophagus. Risk assessment was 
accomplished with a patient-completed over-the-counter medication survey and GerdQ 
questionnaire to identify patients with gastroesophageal reflux disease. When gastroesophageal 
reflux disease (GERD) was identified, providers assessed for the presence of additional Barrett’s 
esophagus risk factors. During the 14-week implementation period, 79 patients were evaluated. 
Over-the-counter medications were used by 64% of patients, and 37% reported using over-the-
counter reflux medication at least monthly. A diagnosis of GERD was identified in 29% of the 
patients. Of the 79 patients completing the tools, 62 were evaluated for Barrett’s esophagus risk, 
with 15% identified as high risk and 6% meeting the criteria for endoscopic screening. The use 
of the over-the-counter survey and GerdQ questionnaire were effective for identification of 
Barrett’s esophagus high risk in this primary care practice. Recommendations were made for the 
use of these tools at the time of colorectal cancer screening referral to facilitate risk assessment 
and concurrent referral for Barrett’s esophagus screening if needed.  
 Key words: Barrett’s esophagus, gastroesophageal reflux disease, disease risk assessment, 
over-the-counter medication reconciliation, GerdQ 
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Chapter One:  Overview of the Problem of Interest 
 There has been a global rise in the incidence of Barrett’s esophagus (BE) over the last 
four decades (Runge, Abrams, & Shaheen, 2015) with a corresponding seven-fold increase in 
esophageal adenocarcinoma (EAC; Hang et al., 2018). BE, found primarily in the West, 
especially in Eastern Europe and the United States (U.S.; Kuipers & Spaander, 2018), is the 
precursor lesion for EAC, which has an 18% five-year survival rate (Peery et al., 2015). The 
diagnosis of EAC is often made after the onset of symptoms causing the five-year survival rate to 
remain static (Iyer & Kaul, 2019). Neither the U.S. Preventative Services Task Force (USPSTF), 
the American College of Gastroenterology (ACG; Shaheen, Falk, Iyer, & Gerson, 2016), nor the 
American Gastroenterological Association (AGA; Spechler, Sharma, Souza, Inadomi, & 
Shaheen, 2011) recommend global screening as it would not be cost-effective due to the 
relatively low incidence of BE in the general population. However, both the ACG and the AGA 
endorse screening patients identified as high-risk for the development of BE (Shaheen et al., 
2016; Spechler et al., 2011).  
 Gastroesophageal reflux disease (GERD) is considered the primary risk factor for BE 
with the most significant risk found in those with more frequent and longer duration of 
symptoms (Runge et al., 2015). GERD symptom management is one of the top ten 
gastrointestinal (GI) reasons for ambulatory visits annually, with GERD being the second most 
common GI diagnosis documented in the ambulatory setting in the U.S. (Peery et al., 2019). 
Despite these statistics, many people remain undiagnosed due to self-treatment with readily 
available over-the-counter medications such as proton pump inhibitors (PPI), histamine-2 
receptor antagonists (H2RA), and other antacids (Kellerman & Kintanar, 2017). The lack of 
communication between patients and health care providers regarding over-the-counter (OTC) 
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medication use is a barrier to diagnosis (Serper et al., 2013). GERD can be empirically diagnosed 
in the primary care setting based upon clinical presentation, or more accurately with the use of a 
validated questionnaire, such as the GerdQ, which provides diagnostic scoring (Gyawali et al., 
2018). The GerdQ should be completed by patients previously diagnosed with GERD and those 
who are self-treating their symptoms to quantify the severity and impact of their disease 
(Gyawali et al., 2018). A risk assessment for BE will only be valid if patients with symptomatic 
GERD are identified (Shaheen, Falk, Iyer, & Gerson, 2016).  
Background Information  
 Barrett’s esophagus is thought to develop as part of the body’s defense mechanism 
against continual tissue insult caused by exposure to a high acid environment (Crews et al., 
2016). Identified risk factors for BE are chronic GERD, male gender, Caucasian race, age 50 
years or older, central obesity, smoking, and family history of BE or esophageal cancer (Runge 
et al., 2015). The prevalence of BE, determined through autopsy and population-based studies, 
ranges from 0.5% to 2% of the general population and from 5% to 15% in those with chronic 
reflux symptoms (Runge et al., 2015).  
Peery et al. (2019) used U.S. Cancer Statistics data from the Centers for Disease Control 
and Prevention (CDC) to identify GI cancer incidence, prevalence, and survival rates for the year 
2014.  Esophageal cancers had an incidence rate of 6.3 per 100,000 (Peery et al., 2019) with a 
lifetime risk of 0.5% and an 18% five-year survival rate (Peery et al., 2015). This low survival 
rate is due, in part, to the late identification of advanced EAC once it becomes symptomatic 
(Crews et al., 2016) with no improvement seen in survival rates over the past several decades 
(Iyer & Kaul, 2019).  Of all GI-related deaths in the U.S., esophageal cancer as an underlying or 
contributing cause of death is ranked sixth, with a rate of 5.6/100,000 (Peery et al., 2019). 
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Esophageal cancer carries a heavy cost burden. Based on 2018 data, the overall annual 
cost of care for all patients with esophageal cancer was approximately $1.7 billion in the U.S. 
(National Cancer Institute, 2020). The annual cost can be broken down into phases of care with 
$683 million spent on initial care, $204 million for ongoing care, and $791 million for care 
during the last year of life (National Cancer Institute, 2020). The per diagnosis cost equates to 
more than $250 thousand for the first and last year of life combined for those under 65 years of 
age, and $184 thousand if diagnosed at age 65 or older (Mariotto, Yabroff, Shao, Feuer, & 
Brown, 2011). 
The estimated worldwide prevalence of GERD is 13%, but this number varies 
geographically (Richter & Rubenstein, 2018). In the U.S., GERD prevalence is estimated 
between 6% and 30%, possibly due to the diversity of the population and the heterogeneity of the 
study tools used (Richter & Rubenstein, 2018). Kellerman and Kintanar (2017) determined a 
sample weighted mean for GERD in the United States at 20%, but the actual prevalence is 
difficult to identify due to minimally symptomatic disease and patients’ ability to manage 
symptoms through self-treatment. 
Significance of the Clinical Problem  
 The American Association of Nurse Practitioners (AANP) defines the overarching goal 
of the primary care practitioner as one that provides patient-centered care, promotes health, and 
prevents disease in partnership with patients and other healthcare services (AANP, 2019). 
However, barriers prevent the provider from developing a comprehensive picture of each 
patient’s health status.  
 Medication reconciliation in the primary care setting is a quality and safety metric set by 
both the Centers for Medicare & Medicaid Services (CMS) and The Joint Commission (TJC). 
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Lack of comprehensive, accurate records of prescription and non-prescription medications, 
herbal remedies, and nutritional supplements is a barrier to preventing patient harm and 
improving the quality of care (Serper et al., 2013). While the integration of data between 
electronic health records (EHR) and retail pharmacy systems has improved the reconciliation of 
prescription medications, there is no such system to alert them to the use of non-prescription 
medicines and other OTC products (Serper et al., 2013).  
 Inconsistent use of patient-specific screening protocols to identify at-risk groups 
requiring additional monitoring or treatment is a challenge to providing quality care (Zabaleta-
del-Olmo et al., 2015). The primary care practitioner focuses on health promotion and the 
generalized care and prevention of common medical conditions, many of which have current 
evidence-based guidelines in place. Primary care practitioners may not have time to incorporate 
further risk assessment and screening tools during a routine office visit (Ireland, Laws, Gordon, 
Thompson, & Esterman, 2018). Additional barriers include increased provider workload and lack 
of knowledge or skills (Zabaleta-del-Olmo et al., 2015). Risk assessment for BE is also 
challenging due to disagreement among gastroenterology societies, inconsistent predictive 
models (Rubenstein & Thrift, 2015), and a lack of established U.S. Preventative Services Task 
Force (USPSTF) guidelines. These factors may prevent the primary care provider from 
delivering comprehensive care to their at-risk patients, reducing the safety and quality of care. 
Question Guiding Inquiry (PICO)  
An urban family practice clinic in north-central North Carolina has not instituted a 
standard of practice for completing medication reconciliation of non-prescription medication use 
for their patients at each visit. The clinic has an interest in determining the type and frequency of 
non-prescribed medications used regularly among their patient population. Because GERD has 
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an estimated prevalence of 20% of the U.S. population (Kellerman & Kintanar, 2017), the clinic 
can expect one in five of their patients to have either a diagnosis of GERD or to experience 
reflux symptoms, with some self-treating with OTC medications. Recognizing the patients taking 
OTC medications for reflux symptoms will improve GERD diagnoses. Improved recognition of 
OTC medication use for GERD will prompt treatment optimization and BE risk assessment, 
which encourages the initiation of early screening. 
 Population. Quality improvement interventions are directed at the medical providers and 
office staff in a primary care medical office.  
Intervention. All medical office providers and staff will be included in the training on 
the OTC medication survey and GerdQ (Jones et al., 2009) tool. Providers will receive additional 
education on evidence-based guidelines related to the assessment and treatment of GERD, 
evaluation of the GerdQ tool results, and use of a BE risk factor assessment tool. The clinic staff 
will use these tools to evaluate OTC medication use, GERD symptoms, and BE risk in adult 
primary care patients age 18 years and older. 
Comparison. Evaluation of the listed medication in the EHR, including OTC 
medications, will be conducted before and after each clinic visit for each patient completing the 
OTC medication tool. Data collected during the project will evaluate the number and percentage 
of patients taking OTC medications that were previously unknown compared to those with an 
accurate and inclusive medication record already documented in the EHR. Additionally, findings 
will identify new diagnoses of GERD and undertreated GERD as a percentage of all adult 
patients seen as new patients or for annual physicals during the implementation period. 
Outcomes. Outcome data will denote adult patients taking OTC medications with type 
and frequency of use, those with new or undertreated GERD, the number at risk for BE, and 
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those with treatment changes based on the information obtained using the implemented tools. 
The goal of this project is to identify adult patients who self-treat with OTC medications to 
enhance comprehensive patient care, to identify those with new or undertreated GERD who are 
at increased risk for BE, and to ensure appropriate referrals for BE screening when indicated by 
elevated risk. 
Summary  
 Common medical problems such as GERD may be missed when providers are unaware 
of patient self-treatment. Lack of knowledge of OTC medication, herbal remedy, and supplement 
use impacts the provision of comprehensive care. GERD, which can be easily self-treated with 
OTC medications, has the potential for significant morbidity and mortality because it is the 
primary risk factor in the development of BE, the precursor lesion for EAC. One method of 
mitigating these consequences is to identify all medications, including OTCs and supplements, 
being taken by patients so that providers can assist them in optimizing treatment and assess the 
risks for comorbid conditions. 
 This quality improvement project will introduce a patient-completed OTC medication 
survey in a primary care clinic where no standard practice to obtain this information exists. 
Patients with a diagnosis of GERD and those self-treating their reflux symptoms will complete 
the GerdQ to assess for the presence and severity of the disease. Using these tools is a step 
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Chapter Two:  Review of the Literature  
A literature review (see Appendix A) was conducted to obtain background information 
and support the development of a quality improvement project to improve the identification of 
gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE) risk in primary care. A 
search for information on disease epidemiology, diagnosis, current evaluation, and treatment of 
GERD and BE was completed. This review focuses on evaluation and treatment methods in 
primary care practice. Validated tools were identified during this search to help diagnose and 
evaluate treatment effectiveness for GERD.  
Self-treatment of reflux symptoms is common in the United States (U.S.) due to the ready 
availability of over-the-counter (OTC) acid-reducing medications. Practitioners may be unaware 
of OTC medication use and, thus, not know of their patients’ difficulty with reflux. An additional 
literature review determined the relative incidence of medication use underreporting and 
methods to improve patient reporting, i.e., through medication reconciliation.  
Literature Appraisal Methodology  
Sampling strategies. The electronic databases PubMed and One Search were used to 
identify the academic literature for this project. Individual and grouped search terms were used 
to identify pertinent literature from the following list: “gastroesophageal reflux disease,” 
“GERD,” “Barrett’s esophagus,” “epidemiology,” “questionnaire,” “GerdQ,” “Reflux disease 
questionnaire,” “RDQ,” “over-the-counter medication,” “non-prescription drugs,” “self-
treatment,” “self-medication,” “provider awareness,” “medication safety,” “medication 
documentation,” “medication reconciliation,” “process implementation,” “GERD questionnaire,” 
“primary health care,” “ambulatory care,” and “patient non-disclosure.”  
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A literature search of peer-reviewed and scholarly work published within the last five 
years conducted using the search terms above resulted in more than 4,500 articles. Of 4,500 
abstracts reviewed, 171 were selected for an in-depth assessment. Other pertinent literature was 
identified by reviewing reference lists of articles found during the initial search adding 16 
additional items. Current clinical practice guidelines for GERD and BE were obtained directly 
from the American College of Gastroenterology (ACG) and the American Gastroenterological 
Association (AGA). Data on OTC medication use in the U.S. was obtained from the Consumer 
Healthcare Products Association (CHPA) website. 
Evaluation criteria.  Evidence for this project encompasses multiple disciplines, 
including nursing, medicine, and pharmacy. Evidence was ranked using Melnyk’s level of 
evidence pyramid (Melnyk, 2011). Several systematic and scoping reviews were identified 
during the literature review. No pertinent meta-analyses nor authoritative opinions were found. 
 The key search terms of “medication reconciliation,” “ambulatory care,” “over-the-
counter medications,”  “self-care,” and “patient non-disclosure” were grouped during the 
literature search. These terms comprise the primary focus of this quality improvement project. 
Due to the volume of literature on these topics, articles were excluded if they did not relate 
directly to two or more of these key terms. North America or European studies were selected 
over studies from other continents due to similarities in demographics and health care. 
Preference was shown for evidence derived from studies conducted in the U.S. 
Literature Review Findings  
 Impact of GERD in primary care. In the United States, GERD prevalence is estimated 
at between 6% to 30%, possibly due to population diversity and heterogeneity of the study tools 
to identify GERD symptoms (Richter & Rubenstein, 2018). GERD prevalence has increased by 
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approximately 50% since the mid-1990s (Kuipers & Spaander, 2018). Kellerman and Kintanar 
(2017) determined a sample weighted mean for GERD in the U.S. at 20%. The actual prevalence 
is difficult to identify due to minimally symptomatic disease and patients’ ability to manage 
symptoms through self-treatment (Kellerman and Kintanar, 2017).  GERD is the primary risk 
factor for BE with the most significant risk found among those with more frequent symptoms 
and longer durations (Runge et al., 2015).  
Due to the prevalence and chronicity of gastrointestinal (GI) disorders, primary care 
providers are often the first clinicians to care for these patients. Practitioners must know the 
evidence-based guidelines for the management of common GI conditions to improve quality of 
life and reduce morbidity and mortality (Gikas and Triantafillidis, 2014). GERD is the fourth 
most common condition treated in primary care (Gikas and Triantafillidis, 2014). In 2009 GERD 
was associated with more than 9 million office visits (Richter & Rubenstein, 2018) and a cost of 
nearly $15.7 billion for prescription acid-suppressing medicines (Peery et al., 2019). GERD 
symptom management is a top ten GI reason for ambulatory visits annually and is the second 
most common GI diagnosis documented in ambulatory settings in the U.S. (Peery et al., 2019). 
The impact of GERD includes disease management costs, and economic and quality of life 
losses related to poor sleep, decreased productivity, and missed work (Kellerman & Kintanar, 
2017). 
GERD diagnosis in primary care. A clinical diagnosis of GERD is based on the 
presence of the typical symptoms of heartburn and regurgitation (sensitivity 30-76%; specificity 
62-96%; Kellerman & Kintanar, 2017). The presence of atypical symptoms such as chronic 
cough, asthma, laryngitis, or dental erosions may also be diagnostic (Kellerman & Kintanar, 
2017). A presumptive diagnosis may be confirmed through empiric treatment and response to 
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proton pump inhibitor (PPI) therapy (sensitivity 78%; specificity 54%; Kellerman & Kintanar, 
2017). A GERD screening questionnaire combined with PPI treatment also correlates the 
diagnosis. Although a diagnosis of GERD can only be presumptive when made in the primary 
care setting, it is a cost-effective and non-invasive way to initiate prompt treatment (Kellerman 
& Kintanar, 2017).  
Despite the prevalence of GERD among the general population, patients may not discuss 
symptoms with their healthcare provider. Once a patient is identified as having reflux symptoms, 
the provider must determine the best management strategy. Bolier, Kessing, Smout, and 
Bredenoord (2015) identified 65 tools for assessment of GERD symptoms, diagnosis, treatment 
response, and impact on patient quality of life.  Because of variability among the tools, no single 
tool applied to all situations. This review provided a guideline for selecting an instrument that 
best meets clinician needs (Bolier et al., 2015). Of the seven tools appropriate for diagnostic 
assessment, only two were useful for this QI project. The GerdQ, translated into five languages, 
is a validated six-item patient-completed questionnaire (Bolier et al., 2015). The Reflux Disease 
Questionnaire (RDQ) is a validated,  12-item, patient-completed questionnaire that has been 
translated into nine languages (Bolier et al., 2015).  
Jones et al. (2009) discussed the development and validation of a patient-centered tool for 
symptom evaluation and assessment of disease impact, the GerdQ questionnaire. The GerdQ is a 
patient-completed six-question tool with a sensitivity of 65% and specificity of 71% (Jones et al., 
2009). Since its initial construction, the GerdQ has been validated in numerous languages and 
settings (Bolier et al., 2015). Grusell, Mjörnheim, Finizia, Ruth, and Berquist (2018) evaluated 
the validity of the GerdQ for assessing atypical presentations of GERD. For patients with cough, 
dysphagia, and globus sensation as the main presenting symptoms, sensitivity ranged from 23-
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45%, while specificity ranged from 73-89%, suggesting that the GerdQ may effectively rule out 
reflux as a cause for atypical symptoms (Grusell et al., 2018). 
The Reflux Disease Questionnaire (RDQ), developed as a diagnostic tool for GERD, is a 
12-item questionnaire assessing six symptoms on a 6-point Likert scale (Bolier et al., 2015). Rey 
et al. (2014) found that the RDQ was useful in primary care to identify GERD based upon the 
patient's perception of whether their reflux symptoms were troublesome. When using a cut-off 
score of three, the RDQ tool sensitivity was 63.2%, and specificity was 80.2% for identifying 
GERD-related troublesome symptoms (Rey et al., 2014). This tool is also useful in assessing 
treatment response to PPIs, with a sensitivity of 65.4% and specificity of 71.8% (Rey et al., 
2014).  
 BE risk assessment in primary care. Globally, GERD and BE incidence has risen over 
the last four decades (Runge et al., 2015) with a corresponding seven-fold increase in EAC 
(Hang et al., 2018). Prevalence of BE, determined through autopsy and population-based studies, 
ranges from 0.5% to 2% of the general population and from 5% to 15% in those with chronic 
reflux symptoms (Runge et al., 2015). 
BE risk factors are chronic GERD, male sex, Caucasian race, age 50 years or older, 
central obesity, smoking, and family history of BE or esophageal cancer (Runge et al., 2015). 
One study found that a history of weekly GERD symptoms before age 30 was associated with a 
15-fold increased risk of BE (Kuipers & Spaander, 2018). Crews et al. (2016) identified male 
gender (OR 3.8; 95% CI 1.7, 8.4) and central obesity (OR 3.0; 95% CI 1.2, 7.7) as additional 
independent risk factors for BE. They found that the probability of having erosive esophagitis or 
BE is 3.7 times higher for patients with three to four risk factors, and 5.7 times higher for 
patients with five or more (Crews et al., 2016). Tobacco use was found to have an odds ratio 
IDENTIFYING BARRETT’S ESOPHAGUS RISK                                                                   22 
(OR) of 2.0 (95% CI, 1.6, 2.3), and central obesity had an OR of 2.0 (95% CI, 1.5, 2.6) (Runge et 
al., 2015). 
At present, there are no validated screening tools to help primary care providers identify 
patients at high risk for BE. The ACG recommends screening men with GERD who have had 
weekly symptoms for over five years when they have two additional risk factors (Shaheen et al., 
2015). Because the risk of BE is much lower in women, Shaheen et al. (2015) suggest 
endoscopic screening on an individual basis and only when multiple risk factors exist. 
OTC medication use. Information obtained from the Consumer Healthcare Products 
Association (2019) notes that 81% of U.S. adults choose OTC medications as their first line of 
treatment for minor symptoms, providing relief to approximately 60 million people who would 
not otherwise seek care. In 2017 more than $34 billion were spent on OTC products, which 
includes $2.6 billion spent on nonprescription heartburn remedies (CHPA, 2019). Many factors, 
including health literacy, access to care, and economics, influence OTC medication choice 
among all adults (Noone & Blanchette, 2018).  Self-care is an essential aspect of consumer 
health as it empowers patients to autonomously manage common conditions, increase 
productivity, reduce healthcare expenses, and is necessary for preventative health (Noone & 
Blanchette, 2018). Although the ready availability of OTC products allows symptomatic self-
treatment of minor illnesses and chronic conditions, healthcare providers are often uninformed 
about their patients’ symptoms and OTC medication use (Noone & Blanchette, 2018). This lack 
of knowledge by providers may lead to increased risk of adverse drug events (ADE), which are 
two to seven times more likely to occur in older adults (Albert et al., 2014) and lead to 178,000 
hospitalizations annually. Several studies estimate that between 35%  and 47% of older adults 
use OTC medications regularly (Albert et al., 2014).  
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OTC medication reconciliation in ambulatory care. Medication reconciliation in the 
primary care setting is a quality and safety metric set by both the Centers for Medicare and 
Medicaid Services (CMS) and the Joint Commission (TJC). Lack of comprehensive, accurate 
records of prescription and non-prescription medications, herbal remedies, and nutritional 
supplements is a barrier to preventing patient harm and improving the quality of care (Serper et 
al., 2013). While the integration of data between electronic health records and retail pharmacy 
systems has improved the reconciliation of prescription medications, there is no such system to 
alert them to non-prescription medicines and other OTC product use (Serper et al., 2013).  
Data about patient disclosure of their health status and medication use is limited. Levy et 
al. (2018) sought to identify the prevalence of intentional nondisclosure of seven types of 
relevant medical information through two surveys, designated as the MTurk and SSI, finding that 
nondisclosure occurred 81.1% (MTurk) and 61.4% (SSI) of the time. Data obtained from the 
same two surveys identified that deliberate nondisclosure of medication occurred 15.5% 
(MTurk) and 10.4% (SSI) of the time (Levy et al., 2018). Some reasons for nondisclosure 
included fear of judgment (81.1% and 64.1%), embarrassment (60.9% and 49.9%), not wanting 
to take up the providers time (45.2% and 35.9%), not thinking that it mattered (38.6% and 
32.9%), and feeling that the provider could not help the problem (27.7% and 28.9%; Levy et al., 
2018). While some nondisclosure may be intentional, Serper et al. (2013) found that there was 
incongruence in what patients believe their providers know about the medications they take. This 
study found that more than 90% of patients thought their provider knew about all their 
prescription and nonprescription medicines, but told the provider about their OTC medication 
use only 46% of the time (Serper et al., 2013).  
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Medication errors, ADEs, and polypharmacy are significant consequences of medication 
list inaccuracies (Holt & Thompson, 2018). Medication reconciliation is one way to mitigate 
these consequences and improve patient safety, but this has been a challenge in ambulatory 
settings due to its time-consuming nature (Holt & Thompson, 2018). TJC identifies medication 
reconciliation as a national patient safety goal across all healthcare settings and, in ambulatory 
care, accepts the showing of a good faith effort as evidence of meeting this goal (Holt & 
Thompson, 2018).  
Numerous interventions have been trialed to improve medication reconciliation in 
ambulatory settings, but there are significant barriers, including time constraints and lack of 
patient participation (Holt & Thompson, 2018). The best method uses a multipronged, 
multidisciplinary approach involving medical providers, pharmacists, nurses, medical office 
staff, and patients (Holt & Thompson, 2018). A scoping review of medication reconciliation 
interventions identified common themes for obtaining information, including patient and 
caregiver interviews, medication lists, medications brought to the clinic, discharge summaries, 
and pharmacy generated lists (McCarthy et al., 2016). The majority of medication reconciliation 
interventions involve interviewing, reviewing medication lists, or bringing medications to clinic 
visits (McCarthy et al. 2016). Brown-bagging, the process of bringing all medicines, including 
OTCs and supplements to the office visit, is a common practice for reconciliation. Multiple 
studies of brown-bagging show that many patients do not bring all of their medications, and the 
process of looking at individual medicine vials and boxes is time-consuming (Sarzynski, Luz, 
Rios-Bedoya, & Zhou, 2014). Sarzynski et al. (2014) found that medication reconciliation was 
improved with structured interviewing, regardless of whether medications were present or not. 
One randomized control trial of two interventions, providing patients with a printed copy of their 
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medication list for review and using open-ended questions, found that medication list agreement 
increased to 75.6%, but only when both interventions were used (Wolff, Nowacki, Yeh, & 
Hickner, 2014). Common among all of the studies in this literature review was the theme of 
inconsistent reconciliation of OTC medications. A study aimed at improving OTC medication 
reconciliation used a human body diagram and symptom list to prompt patients to provide a two-
week recall of nonprescribed medicines taken (Jarrett, Cochran, Baus, & Delmar, 2019). Jarrett 
et al. (2019) identified improvement in documentation of OTC medications in 82%, PRN 
medications in 3%, and herbal supplements and vitamins in 28% of the records following the 
intervention. Patient prompting and open-ended questions showed the most promise for 
improving the reconciliation of OTC medications. 
Facilitators of medication reconciliation include engaging patients in the process and 
instructing them on its importance, engaging clinic staff and providing education and feedback, 
collaborating with outside providers, integrating the process into the current workflow, and low 
cost (McCarthy et al., 2016). Another qualitative study looking at barriers and facilitators of 
medication reconciliation in primary care found that nearly all patients perceived the value 
obtained through the process (Uhl, Muth, Gerlach, Schoch, & Müller, 2018). Patient barriers 
revolved around reluctance to provide information due to a sense of lost autonomy, not wanting 
to disclose sensitive diagnoses, lack of awareness of the potential harm nonprescribed 
medications can cause, and fear of having to justify their medicine use (Uhl et al., 2018). The 
most prevalent provider barrier found among reviewed studies on medication reconciliation in 
ambulatory care was time poverty.  
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Limitations of the Literature Review Process 
Limitations and gaps in the current literature were discovered through the review and 
synthesis process. Medication reconciliation processes often focused on times of transition 
between care settings rather than at every appointment. There was limited evidence on ways to 
elicit information on over-the-counter medications and supplements, an area of concern in almost 
every study. Additionally, medication reconciliation most often relied on the use of electronic 
health records, which may not provide the appropriate tools for implementation of a thorough 
process in a small primary clinic. Few tools were identified to aid specifically in the OTC 
medication reconciliation process. 
Discussion  
 Conclusion of findings. This quality improvement project was developed to identify 
patients at high risk for BE, with a long-term goal of preventing esophageal adenocarcinoma. 
Because GERD is the primary risk factor in the development of BE, identifying patients with 
GERD or who are self-treating reflux symptoms is essential. GERD is a widespread disease that 
impacts one in every five people, making it likely that the primary care provider will see four to 
five patients per day with this condition. Because GERD is easily treatable with OTC 
medications, patients may not discuss their reflux symptoms with their provider. The common 
problem of lack of disclosure regarding OTC drugs and inconsistencies remaining in the EHR 
after medication review was evident in several studies that evaluated medication reconciliation. 
When inconsistencies were discovered during review processes following medication 
reconciliation, omissions universally involved OTC drugs.  
 Due to GERD and reflux symptom responsiveness to self-treatment, OTC medications 
are frequently used for symptom management. Patients who take OTC medications to treat reflux 
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symptoms are less likely to notify their primary care provider when there is no routine process to 
evaluate the type or frequency of OTC medication use. Identification of GERD is essential in 
gauging Barrett’s esophagus risk. An OTC medication survey and provider review of frequent 
OTC medicine use will identify patients who should be assessed more thoroughly for GERD. 
The validated tool, GerdQ, is a short, patient-completed form that aids in the diagnosis of GERD 
in primary care. Provider identification of a GERD diagnosis provides the opportunity for 
education on lifestyle modifications, optimization of treatment, and assessment of additional risk 
factors for BE. In the short term, better management of GERD will improve patients’ quality of 
life.    
Advantages and disadvantages of findings.  The primary benefit of the proposed 
project is the enhancement in comprehensive, patient-centered, and holistic care through 
improved provider knowledge of all medications and troublesome symptoms the patient may be 
experiencing. The format of the intervention should prompt increased communication about 
health issues experienced by patients, leading to better management. Reducing symptom burden, 
drug interactions, and the potential for adverse drug events, are other important outcomes to be 
considered.  
The primary disadvantage of implementing this project is the potential for an increased 
workload due to new forms and additional documentation. Time spent on paperwork diminishes 
time caring for patients and reduces clinic productivity. Buy-in from all staff may be difficult if 
other providers don’t recognize a gap in care or are not involved in tool or process development. 
Utilization of findings in practice change.  The literature review identified a gap in 
practice related to provider-patient communication and knowledge of patients’ medication use, 
particularly OTC medications. Patients may not discuss self-treated problems with their primary 
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care provider, and the provider may not routinely ask about self-care. OTC medications are often 
overlooked during routine medication reconciliation, and patients may not feel that it is essential 
to include non-prescribed drugs. Studies reviewed identified several ways to help reduce 
omissions during medication reconciliation, including patient prompts and interviews regarding 
their medicines. A tool that prompts patients to consider and document their OTC medication 
usage may help to close the gap. When this tool is followed by medical provider review and 
open-ended discussion, a complete medication list can be generated. Although not well studied 
in primary care, accurate and complete medication records in the hospital setting are shown to 
reduce the risk of medication duplication, drug-drug interactions, and adverse events. 
The second piece to this project is identifying patients at increased risk for Barrett’s 
esophagus. An accurate medication record provides the primary care provider with knowledge 
about their patient’s health concerns. Any patient who is taking medications regularly to treat 
GERD or reflux symptoms will complete the GerdQ, a validated diagnostic tool to assess the 
likelihood and severity of GERD. With this knowledge, the provider will consider the patient’s 
additional risk factors for Barrett’s esophagus and, if evaluation identifies high risk, will manage 
according to ACG recommendations. 
 Barriers to implementing new programs in ambulatory care are identified in the 
literature. The most problematic barrier to implementation of this project at a primary care clinic 
is time poverty. Patients are scheduled every 20 minutes, and there is not a nurse or certified 
medical assistant (CMA) to room patients or complete pre-visit screening tools. Providers often 
room their patients and perform other duties such as lab draws. The additional time it takes to 
review another document and record additional medications may take time away from direct 
patient assessment and evaluation.  
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The most essential facilitator is the recognition that a lack of knowledge about OTC 
medication use in their patients is problematic. Buy-in and involvement in process development 
are essential factors to consider. Early and ongoing discussions regarding the project and 
processes, along with provider and staff education prior to implementation, will facilitate a 
smooth implementation process.  
Summary  
 A patient-completed OTC medication survey will be introduced in a primary care clinic 
to improve the accuracy and completeness of the patients’ medication records. Patients who are 
taking prescribed or OTC acid reflux or heartburn medications will complete the GerdQ to 
establish a diagnosis of GERD and determine the severity of the symptoms. New OTC 
medications discovered with the OTC medication survey may encourage communication 
between the provider and patient about their health and troublesome symptoms, leading to 
comprehensive, patient-centered care. A diagnosis of GERD should prompt additional review by 
the medical provider to assess for other risk factors of Barrett’s esophagus, which may indicate 
that screening is needed.  
This quality improvement project meets the Institute for Healthcare Improvement (IHI, 
2020) Triple Aim objectives of improved per-capita costs, the experience of care, and population 
health. As identified by CMS and TJC, medication reconciliation is an important measure that 
enhances the quality and safety of patient care. Patients believe that provider knowledge about 
their medications is significant to the receipt of good care as well. Complete and accurate 
medication records can reduce drug-drug interactions and adverse drug events preventing 
emergency department visits and hospitalizations. Patient-completed surveys and assessment 
tools such as the OTC medication survey tool and GerdQ allow the medical provider to gather 
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essential data without reducing their time with the patient. These tools may also improve 
communication with patients by prompting discussion about changes in their health. Adequate 
treatment of GERD is shown to improve patient quality of life by increasing productivity and 
reducing time away from work. Additionally, knowledge of a GERD diagnosis will provide the 
opportunity for providers to assess for high risk of BE, allowing patients to be screened early. 
Early screening increases the potential to prevent EAC, thereby reducing the associated financial 
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Chapter Three:  Theory and Concept Model for Evidence-based Practice  
This chapter examines the theory and concepts that ground evidence-based practice 
change.  Once a problem has been identified, the clinician must identify the general ideas or 
concepts related to the problem. Analysis and mapping the interactions among the pertinent 
concepts permit the project team to visualize concept associations and their influences on one 
another. Theory provides a framework for project development and implementation and guides 
the project along a prescribed path. This project will use the Iowa Model of Evidence-based 
Practice.  Lewin’s Change Theory will be incorporated in the Iowa Model framework to enhance 
implementation, adoption, and sustainability. 
Concept Analysis  
 Defining the ideas presented in this quality improvement project provide the background 
for understanding the underlying concepts and their connections to each other (See Appendix B). 
These interwoven concepts impact the project and guide the interventions and goals.  
 Patient self-care. The concept of self-care concerns how a person understands and 
addresses their personal needs to optimize health. The mechanisms of self-care include activities 
to improve physical, psychological, spiritual, and social well-being. In the project’s context, self-
care relates to the use of over-the-counter (OTC) medications and supplements to prevent illness, 
improve health, or treat symptoms. 
 Patient nondisclosure. Nondisclosure of information to a healthcare provider can be an 
intentional or unintentional omission.  Patients may not realize that self-care activities may 
interfere with prescribed care. Patients may be embarrassed or fear judgment from their provider 
about their self-care choices. Lack of disclosure influences the provider’s ability to have a 
comprehensive view of patient health.  
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 Patient-provider communication. Communication between patients and healthcare 
providers is multimodal through oral, written, and electronic communication, non-verbal cues, 
visual prompts, and patient-completed tools. Using several communication methods during 
patient encounters helps overcome barriers, prompts discussion, and improves holistic care. 
Providers who display open and non-judgemental behaviors influence patient trust leading to 
enhanced communication. 
 This project uses an OTC medication survey to mitigate one patient-provider 
communication gap. The tool is designed to prompt patient recall of OTC medication use. 
Discussion of the survey contents during the patient encounter enhances the provider’s 
understanding of patient self-care actions and health-related goals.  
 Medication reconciliation. Medication reconciliation is the process of identifying and 
documenting all prescribed and OTC medications, herbal remedies, and supplements in the 
patient health record. It is essential for provider understanding of patient self-care and health 
status and should be completed during every patient encounter. Reconciliation methods vary 
among different practices and care settings. When a medication reconciliation process is used 
consistently, medication records are more accurate. Primary care providers are coordinators of 
patients’ overall care and are essential in preventing drug interactions and adverse events. 
 Disease risk assessment. Risk assessment in healthcare is a crucial practice that 
influences health and outcome goals. Risk assessment involves evaluating the factors that impact 
health negatively. Risk is best assessed when the provider is fully aware of all the factors that 
influence the patient’s health and well-being. Assessing modifiable and non-modifiable risk 
factors leads to the development of a care plan that mitigates risk, prevents disease, and promotes 
health. Patient-determined goals should guide risk assessment, disease screening, and treatment. 
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Absent or incomplete risk assessment leads to missed screening and preventive treatment 
opportunities. Alternatively, it may lead to unnecessary screening, needless testing, and 
increased healthcare costs. In disease processes with low population prevalence, such as Barrett’s 
esophagus (BE), risk assessment is necessary to determine which patients should be screened.   
Theoretical Framework  
 A theoretical framework helps to study a problem of interest and evaluates its interrelated 
concepts. This framework guides the development, implementation, and evaluation of a Doctor 
of Nursing Practice (DNP) scholarly project. Through a synthesis of the literature, current 
evidence can be used to solve problems and guide practice change. 
 Iowa Model of Evidence-Based Practice. Incorporating best practices in healthcare is 
challenging due to a changing healthcare environment, the discovery of new knowledge, and 
provider time demands. The Iowa Model of Evidence-Based Practice, based on Roger’s 
Diffusion of Innovations, delivers a framework to guide practitioners from defining a problem of 
interest to translating evidence into practice (see Appendix C; Iowa Model Collaborative [IMC], 
2017). The IMC (2017) provides tools for each step to aid project development. The Iowa Model 
identifies decision points to streamline the process of improving care quality. These steps align 
with the framework that guides the DNP scholarly project. 
 The first step of any evidence-based project is discovering areas requiring change, and 
then defining the problem. The Iowa Model uses a PICO (Population, Intervention, Comparison, 
Outcomes) statement as a guide (IMC, 2017). After adequately defining the problem, the first 
decision point is reached: Is this problem a patient, organization, or system priority? If so, a 
multidisciplinary team should be formed, followed by the development of an action plan and 
timeline (IMC, 2017). 
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 Step two is a review and synthesis of the literature to locate and evaluate current evidence 
that supports the desired change (IMC, 2017). After the literature is evaluated, the second 
decision point is reached: Is there enough available evidence to support the change? If there is 
inadequate evidence to inform the change, several options exist: conduct research to fill the gap 
or expand on or develop additional topics to address the need (IMC, 2017).  
 Once sufficient support is identified, the team can proceed to step 3:  project development 
and testing the practice change. The revised Iowa Model recommends changes that are patient-
focused rather than organization-focused (IMC, 2017). Additionally, identifying resources and 
implementation strategies should be addressed (IMC, 2017). Appropriate implementation 
strategies encourage stakeholder support through increased awareness and interest, building a 
knowledge base, and improved commitment (Cullen & Sigma Theta Tau International, 2017). 
The implementation phase may pass through several iterations if outcomes from pilot testing are 
not as anticipated. Decision point three occurs following implementation: Is the change 
appropriate for adoption (IMC, 2017)? If the answer is no, then reevaluation and redesign should 
occur. If the practice change is affirmed, the project team should proceed to the final steps of 
integrating and sustaining the practice change, and disseminating the findings (IMC, 2017). 
 White and Spruce (2015) used the Iowa Model to implement an evidence-based guideline 
for handwashing to reduce the incidence of surgical site infections in a perioperative setting. The 
project team discovered that using multiple implementation strategies led to greater acceptance 
and support for practice change (White & Spruce, 2015). This suggests that a project has a higher 
chance of success and sustainability when several appropriate implementation strategies are 
used. 
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Application of the Iowa Model to practice change.  
 Step one: Defining the problem. In the U.S.,  gastroesophageal reflux disease (GERD), 
BE, and esophageal adenocarcinoma (EAC) are increasing in prevalence and often remain 
undiagnosed until the late stage. One in five patients seen in primary care will have GERD, but 
patients often self-treat symptoms without informing their provider. Anecdotal evidence and the 
literature informed us that patients do not routinely discuss OTC medication use or self-treated 
problems unless prompted or when there was a medication reconciliation system in place. 
 Decision point 1: Is this problem a priority? Implementing a medication reconciliation 
process was a priority. A provider’s ability to provide comprehensive, patient-centered care 
relies on having complete knowledge of patients' problems, health goals, prescribed treatments, 
and self-care. Some self-care measures, such as OTC medication use, can interfere with 
prescribed treatments through interactions or adverse events. Lack of provider knowledge 
regarding self-treated problems impedes treatment optimization and screening interventions, 
which influence long-term outcomes. 
 Step 2: Literature review and synthesis. The literature confirmed the extent of the 
identified issues and offered evidence that patient non-disclosure warrants intervention. 
Medication reconciliation was shown to improve disclosure of OTC medication use. Patients 
with self-treated GERD symptoms would be identified, assessed for symptom severity, and 
screened for BE risk. 
 Decision point 2: Is there enough evidence to support the change? The evidence found 
was sufficient to support a change in practice. A tool prompting patients on their OTC 
medication use was developed for use in a primary care clinic where no process existed. Patients 
taking reflux medications used the GerdQ questionnaire to evaluate the severity and impact of 
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their symptoms. The medical provider optimized reflux treatment and determined the patient's 
risk of BE based on the presence of other risk factors following the American College of 
Gastroenterology (ACG) recommendations. 
 Step 3: Implemention of practice change. The clinic staff and providers worked with the 
project lead to design tools and processes. Teamwork improved buy-in from those involved in 
the process. Educational sessions were conducted with the staff before implementation. The 
process was patient-centered and multidisciplinary using tools designed to prompt patient 
disclosure of self-treatment measures and a validated tool to evaluate and diagnose GERD. Using 
PDSA (Plan, Do, Study, Act) cycles, reevaluation of the process occurred every two to three 
weeks with revision of the process occurring as the stakeholders identified problems.  
 Decision point 3: Is the change appropriate for adoption? Following the 
implementation processes, frequent evaluations, and assessment of project data led to project and 
process modification to meet clinic objectives. Frequent revaluation of the data showing early 
positive outcomes reinforced buy-in to the process and justified the need to adopt the change into 
practice.  
 Step 4: Integrate and sustain practice change. By continuing to work with clinic staff to 
assess and modify the process, full integration into the practice setting would be achieved. 
Modifications focused on how to best meet the need of the patients, staff, and clinicians. The 
final step to fully integrate the practice change would be the inclusion of the tools within the 
electronic health record (EHR). Patients with access to the patient portal would be able to use the 
tools before attending their appointment. Integration with the EHR would reduce staff and 
provider time burden and improve clinic flow. 
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 Step 5: Disseminate the findings. Project findings were disseminated through a final 
report and presentation to the clinic staff, and by virtual podium presentation at the East Carolina 
University College of Nursing. Upon completion, the DNP scholarly project paper will be 
uploaded to the ScholarShip, East Carolina University’s institutional repository of scholarly 
works. 
Evidence-Based Practice Change Theory.  
Lewin’s Change Theory. Change in healthcare is inevitable. Discovery of new evidence 
to guide practice, shifting practice environments, and changes in patient, provider, and 
organizational expectations cause demand for change that promotes improvement in the quality 
of care. Implementing change among these competing interests is challenging and best managed 
when guided by theory.  
Lewin’s Change Theory (see Appendix D) is a three-step framework for influencing the 
contextual factors that facilitate or impede change (Manchester et al., 2014).  Step one, 
unfreezing, involves determining the need for change, identifying the stakeholders involved, and 
recognizing the barriers and facilitators to changing practice (Manchester et al., 2014). To 
facilitate the unfreezing process, the driving forces for change must overcome the resistant forces 
to upset the status quo (Manchester et al., 2014). Once unfreezing occurs, movement, the second 
step, can begin. Movement is the implementation process involving cycles of evaluation, 
reassessment, and refinement, which occur until the anticipated outcomes are achieved, and the 
process or behavior becomes routine (Manchester et al., 2014). Once the policy, practice, or 
behavior is widespread and becomes an accepted part of the practice, refreezing can begin. 
Refreezing, the third step of Lewin’s Change Theory, involves using reinforcement measures 
that lead to the adoption and sustainability of the practice change (Manchester et al., 2014).   
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Application to practice change. Lewin’s change theory directly aligns with steps three 
and four of the Iowa Model for Evidence-based Practice Change because it enhances the 
framework for implementation, adoption, and sustainability. 
Unfreezing.  The clinical problem identified at the project site is a lack of complete 
medication reconciliation at each visit. Incomplete medication reconciliation impacted the 
providers’ ability to provide comprehensive patient care. Providers' lack of knowledge regarding 
patient self-treatment placed patients at risk for adverse drug effects, drug interactions, and 
missed diagnoses. The stakeholders were the clinic staff, providers, and patients. Driving forces 
were the providers’ desire to provide comprehensive care, cost-effective program to implement, 
and having a project lead from outside of the clinic workforce. Restraining forces included a 
negative impact on time management and clinic flow and increased work caused by the necessity 
for manual input into the EHR.  Including staff and providers in tool development and 
implementation process, and providing education on the problem background, expected 
outcomes, and implications to their practice assisted in overcoming the status quo. Piloting a 
limited OTC questionnaire to judge workflow and time demands eased concerns. Providers 
completed a survey after each applicable patient visit. The post-visit survey indicated when new 
problems, medications, a new diagnosis of GERD, or high risk for BE was identified, and 
identified treatment plan changes.   
Movement. Step two began with project implementation. A pilot OTC questionnaire 
limited to medications taken for gastrointestinal (GI) complaints permitted evaluation of the 
workflow. As staff members became accustomed to the reconciliation process, additional OTC 
medication groups, such as pain medicines, cold and sinus medicines, or topical products, were 
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added to the questionnaire. Once every two to three weeks, staff and providers discussed how the 
process worked with the team lead, and adjustments were made as needed.  
Refreezing. As the project neared completion, measures to reinforce the change were 
implemented. These included posters reminding patients to discuss their OTC medications with 
providers and EHR prompts reminding providers to ask about OTC medication use. 
Dissemination of project findings of positive outcomes reinforced the change, leading to 
adoption. Integration of prompts into the EHR and using the electronic patient portal to send 
OTC medication surveys before appointments should ensure project sustainability. 
Summary.  
 The ability to translate evidence and facilitate evidence-based practice change is the 
hallmark of the DNP-prepared nurse. Identification of practice and organization problems and 
their related concepts, and looking at issues from multiple perspectives are valuable skills when 
developing a practice change project. Visualization of concept relationships through concept 
mapping further defines the problem and suggests potential solutions. Evidence-based practice 
change is a complex, multidimensional process that is best guided using a framework based on 
sound theory.  
 This project uses both the Iowa Model for Evidence-based Practice Change and Lewin’s 
Change Theory. Using a step-wise process, the Iowa Model guides the project, beginning with 
the development of a problem statement, through conducting a literature review, to 
implementation, and ending with the integration of the practice change and disseminating the 
findings. When used in conjunction with Lewin’s Change Theory’s unfreezing, movement, and 
refreezing processes, implementation and integration will achieve greater success. 
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Chapter Four:  Pre-implementation Plan 
A successful quality improvement (QI) project begins with a detailed plan. This chapter 
discusses the pre-implementation process, which began with defining the purpose. Active 
communication among the project team members assessed their readiness for change. Project 
pre-implementation involved risk analysis, project budgeting, and development of project tools. 
The institutional review board (IRB) process is discussed, along with other methods used to 
ensure patient safety.  
Project Purpose 
 The project's purpose was to identify (1) previously unreported over-the-counter (OTC) 
medication use, and (2) to quantify gastroesophageal reflux disease (GERD) symptoms. These 
variables determine which patients are at risk for developing Barrett’s esophagus (BE). After the 
OTC medication survey and GerdQ are implemented, the primary care provider will determine 
which patients have unidentified or undertreated GERD. The identification of GERD prompts 
the assessment of additional BE risk factors and guides the plan of care. 
Project Management 
Organizational readiness for change. When considering healthcare delivery changes, 
the resulting changes, or outcomes, should be patient-centered. Discussion with the site 
champion identified several areas to improve comprehensive patient care at the project site. 
Anecdotal practice evidence suggested that patients often required prompting about OTC 
medication use, which often led to the discovery of additional health issues. Understanding of the 
lack of a standardized assessment of OTC medication use and the desire to provide patient-
centered care drove the organization’s readiness for change. The principle of patient-centered 
care is exemplified by the following:  discovery of self-medication and underreported GERD 
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symptoms leads to the ability to assess BE risk, identify potential drug-drug interactions, and 
prevention of adverse drug events.  
The Health Resources and Services Administration (HRSA, n.d.) identified three 
characteristics that define organizational readiness: leadership commitment to QI, clinician 
acknowledgment of the value of QI, and the ability to collaborate. The site champion expressed 
interest in the proposed project and garnered support from the clinic’s medical director. Due to 
the small size of the project site, the entire staff worked with the project lead to foster change and 
improve quality, patient-centered care for their patients. 
 Interprofessional collaboration. The project team consisted of the DNP student project 
lead, the DNP faculty advisor, the family nurse practitioner (FNP) site champion, the physician 
medical director, a new-to-practice adult-gerontology nurse practitioner (AGNP) provider, a 
certified medical assistant (CMA), and the office manager. The project lead was responsible for 
QI project coordination and development through collaboration with the site champion and 
support of DNP project faculty. Additional project lead responsibilities included team education, 
data compilation, and providing project support throughout the QI project.  
During implementation, the CMA provided the OTC medication survey and GerdQ tool 
to all new adult primary care patients and adult patients presenting for annual physicals at 
appointment check-in. All three providers reviewed the OTC medication survey for unreported 
medication use, scored and reviewed the GerdQ tool, evaluated BE risk factors, and addressed 
plan-of-care changes. The office manager provided support to the CMA and monitored for 
project-induced workflow issues. All forms were collected and secured in the site champion’s 
office daily. In addition to project participation, the medical director monitored the impact on 
clinic productivity and workflow. 
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Risk management assessment. As a part of risk management, a SWOT analysis was 
conducted during pre-implementation to assess the strengths, weaknesses, opportunities, and 
threats related to this QI project. These variables had opposing positive and negative impacts on 
the project. By amplifying the strengths and opportunities, the weaknesses and threats were 
minimized. 
Strengths.  There were several strengths that supported this QI project. Voluminous data 
on the increase in GERD, BE, and EAC prevalence in the U.S. illustrated the depth of the 
problem. Medication reconciliation was a quality and safety metric across all care settings in the 
U.S. Working with a small practice site allowed for better communication and cooperation 
among team members. There was leadership support for quality improvement initiatives, and 
there were no front-end clinic costs to implement at this project site. 
Weaknesses. Several weaknesses impacted this project. There were a lack of best 
practices and validated tools for OTC medication reconciliation. The OTC medication 
reconciliation and GerdQ tools were completed on paper, rather than integrated into the EHR. 
Manual medication reconciliation into the EHR caused increased staff workload.  The project 
lead compiled data manually. 
Opportunities. Involving all clinic staff in the QI process supported a sense of project 
ownership, which encouraged participation. By taking advantage of the site champion’s 
enthusiasm, project buy-in was improved. The clinic’s patient population matched the BE risk 
profile, which improved the odds of impacting patient’s long-term health. Integrating the tools 
into the EHR and allowing patients to complete tools pre-visit would improve participation and 
reduce staff workload. 
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Threats. An early threat to project success was that initial discussions and project 
planning only included the site champion. This could have led to resistance to participation. 
Another project completion threat was the potential for lack of recognition by patients of the 
importance of including OTC medications during reconciliation. A financial threat was that 
back-end costs to integrate the project tools into the EHR might be prohibitive. Finally, some 
patients may not possess the technology or skills to access the tools if integrated into the EHR.  
Organizational approval process. During the Fall, 2018 clinical practicum, the project 
lead encountered several instances of unknown OTC proton pump inhibitor (PPI) use by clinic 
patients. Additional investigation highlighted data collection inconsistencies on OTC medication 
use. Discussion of the increasing prevalence of GERD, BE, and EAC and measures to improve 
identification occurred with the site champion over several weeks, and possible methods to 
improve recognition were discussed. A mock-up tool for the evaluation of OTC medication use 
and the GerdQ tool were presented for evaluation. The site champion expressed concern that the 
full OTC medication survey would lead to a sudden increase in workload, negatively impacting 
workflow. This led to an agreement to implement this tool slowly, surveying OTC GI 
medications first, and then adding other OTC medication classifications after workflow impact 
was assessed. The medical director was presented with the project outline and agreed to allow 
the QI project to proceed. Final approval was received, and a letter of support (See Appendix E) 
was obtained from the FNP serving as site champion. 
Information technology. The clinic EHR was used to determine general patient 
population demographics and the average number of adult primary care patients seen per week. 
Microsoft® Office and Excel were used to compile, analyze, and display data using tables, charts, 
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and graphs. Microsoft® PowerPoint was used to create an initial educational presentation for the 
project team and final project poster displaying the data and project outcomes.   
Cost Analysis of Materials Needed for Project 
 The financial costs of implementing this QI project were minimal. They primarily 
consisted of administrative costs associated with printed educational materials, and the OTC 
medication survey, GerdQ, and post-visit provider survey. Additional costs included food 
provided during a Lunch-and-Learn education session. Travel expenses for ten round-trip visits 
to the clinic were included in the budget. See Appendix F for the proposed QI project budget.  
Non-monetary costs included time away from work and personal time used to complete the QI 
project.  
 Use of a personal LaserJet printer to print educational handouts, OTC medication and 
post-visit provider surveys, and GerdQ tool provided administrative cost savings. Additionally, 
all data was compiled and analyzed by the project lead, leading to no added personnel costs.  
Plans for Institutional Review Board Approval 
 Permission to move forward with the IRB process was first received from the project 
faculty after reviewing the project plan and tools. The East Carolina University (ECU) IRB 
process involved completing a QI/program evaluation self-certification tool (See Appendix G) to 
assess the type of IRB process required. This initial IRB review determined the project to be 
quality improvement; therefore, the full IRB process was not needed.  The project 
implementation site, a small single-office family practice, did not have an IRB process. They 
followed the policies set forth during the ECU review process. 
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Plan for Project Evaluation 
Demographics. Data obtained using the DNP Project Data Collection Tool (See 
Appendix H) was compiled and presented as aggregate quantitative data representing new adult 
patients and patients presenting for annual physical appointments. This data identified the 
number of patients seen, number completing the OTC medication survey and GerdQ, new GERD 
diagnoses, and the number considered at risk for BE. The project lead reviewed each completed 
BE risk assessment to identify the number of male patients with GERD with two additional risk 
factors. No individually identifiable health information was collected. This data was reported 
using frequency counts and percentages, i.e., the total number of patients seen compared to a 
new diagnosis of GERD, or diagnosis of GERD compared to high risk of BE. This information 
was presented in table format. 
Outcome measurement. Both process and outcome measures were identified during this 
QI project. Process measures monitored the number of OTC surveys and GerdQ tools completed, 
the number of GerdQ tools correctly scored, and the number of provider post-visit surveys 
completed. Process measures determined whether the project was fully implemented to include 
all applicable patients. Full implementation improves the odds that all at-risk patients would be 
identified. Outcome measures included identification of the number of new patients with GERD, 
patients at risk for BE, and disposition based on this information. Three disposition levels were 
identified: (1) monitor/continue current treatment, (2) modification of treatment plan through 
lifestyle modifications or medication changes, and (3) referral to GI. Outcome measures 
provided an indicator of the impact of the project on improved patient care. 
Evaluation tool. The OTC medication survey was explicitly created for this project to 
identify the types and frequency of OTC medication usage among adult primary care patients 
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(See Appendix I). This tool used written prompts to aid patient recall of the types of OTC 
medications they used. Patients taking OTC medications to treat upper GI symptoms such as 
heartburn, acid reflux, or regurgitation completed the GerdQ, a validated six-item tool used to 
diagnose and quantify the severity and impact of GERD in the primary care setting. The GerdQ 
was initially evaluated with a sensitivity of 65% and specificity of 71% (Jones et al., 2009). 
Since its development, the GerdQ has been revalidated numerous times with similar results in 
English and several other language translations. Permission for use was obtained from the owner, 
AstraZeneca (See Appendix J), with copies of the tool provided in English and Spanish language 
translations (See Appendices K and L). The GerdQ scoring tool was also provided (See 
Appendix M). 
Providers were given a five-item post-visit survey to summarize each patient visit (See 
Appendix H). The first four questions consisted of yes/no response items that asked if new 
patient information was discovered because of the OTC medication survey or GerdQ, if the 
information prompted a treatment change, and if high risk for BE was identified. A treatment 
change was defined as education, medication, testing, referral, or other treatment. The fifth item 
asked the provider to determine the patient disposition from five choices and to circle all options 
that applied. 
Data analysis. Descriptive statistics, percentages, and measures of central tendency were 
used to present the quantitative data obtained during implementation. Compiled information 
from the collected surveys and GerdQ tool was entered into a Microsoft® Excel spreadsheet 
describing the data obtained during each PDSA cycle throughout the implementation period. All 
GerdQ tools were reviewed each week for correct scoring. When scoring errors were identified, 
the scoring instructions were reinforced with the site champion. Each of the tools discussed was 
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new to this practice. Thus, there were no practice benchmarks with which to compare. 
Additionally, there were no defined quantitative screening parameters for BE. 
Data management. The surveys and GerdQ were collected and stored by the site 
champion at the end of each clinic day. The project lead reviewed and compiled the data at the 
project site every two to three weeks. Because no personally identifiable health information was 
collected, no special procedures were required to protect the data. All data were stored on a 
password-protected laptop computer and backed up on a password-protected desktop computer. 
A backup of the data occurred biweekly. The surveys and GerdQ tools remained at the project 
site and were shredded at the completion of the project. Aggregate project data was available for 
review with site team members and project faculty during the implementation period. Only the 
project lead had access to editable Microsoft® Excel files.  
Summary 
 A great deal of planning occurred during pre-implementation. This was a complex, 
multistep process that ensured a successful QI project. The process began by defining the 
project’s purpose: to identify patients at high risk for BE.  Assessing readiness for change and 
project risk was essential.  The ECU IRB identified this project as quality improvement, 
indicating there was minimal risk of harm. No personally identifiable information was obtained, 
and all data was presented in aggregate, ensuring patients’ health information remained secure.  
 Developing the OTC medication survey, selecting the GerdQ, and defining methods for 
data compilation, analysis, and management required a great deal of thought and time. Planning 
during the pre-implementation phase ensured a well-developed project and provided a 
framework for successful implementation. 
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Chapter Five:  Implementation Process 
Successful implementation can only occur after thorough planning during the pre-
implementation phase. The implementation process included the delivery of the assessment and 
data collection tools, quality improvement (QI) project team education, ongoing process 
assessment during the implementation period, and compilation of data. This chapter describes the 
implementation process and how the process was adapted to meet the needs of the project site.  
Setting 
        The setting for this Doctor of Nursing Practice (DNP) project was a privately-owned single-
office family practice clinic located in urban north-central North Carolina. This practice is 
unaffiliated with the local university medical centers but has access to each center’s patient 
medical records via the Epic electronic health record (EHR). The primary care population served 
by this entity consists primarily of patients with private health insurance and Medicare, with less 
than 10% being self-pay. Greater than 80% of their patients are adults age 18 years or older. 
Caucasians comprise 70% of their patient population. The three providers at this practice see 
approximately ten adult primary care patients each per eight-hour day, with one to two new or 
annual physical patients seen per day. Roughly 20% of the patients seen at this clinic are being 
treated solely for opioid dependence and are not considered part of the primary care population. 
 It is estimated that 20% of the US population has gastroesophageal reflux disease 
(GERD; Kellerman and Kintanar, 2017). The demographic profile of an at-risk person for 
Barrett’s esophagus (BE) is a Caucasian male over 50 years of age with central obesity and a 
current or past smoking history who has chronic GERD. The patient population at this clinic 
made it ideal for the implementation of this project to identify patients at high risk for BE. 
Additionally, a high percentage of patients at this project site are insured, which will allow at-
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risk patients to afford plan-of-care changes for GERD treatment and to obtain screening 
examinations for BE if warranted.  
Participants 
 Because this DNP project represented a practice change involving all personnel in this 
small practice, all staff agreed to participate in the project team. The project team consisted of 
the family nurse practitioner site champion, a new-to-practice adult-gerontology nurse 
practitioner, the physician medical director, a certified medical assistant (CMA), and the office 
manager. Education on the rationale and purpose of the project, and on completing, scoring and 
evaluating the over-the-counter (OTC) medication survey and GerdQ, was provided to the 
project team. The providers received additional instruction on evaluating BE risk and completing 
the post-visit provider survey.  
 The project team was instructed to provide the OTC medication survey and GerdQ to all 
primary care patients age 18 years or older who present for a new or annual follow-up visit. 
Patients younger than 18 years of age, any patient being seen urgently or routine follow-up, and 
those seen only for opioid dependence were excluded. Patients also had the option to refuse to 
complete the OTC medication survey and GerdQ tool. 
Recruitment 
        Recruitment began when the project lead approached the site champion during the project 
development phase. The site champion presented the project idea and general framework to the 
medical director and obtained her verbal agreement for this clinic to implement the project. After 
this verbal agreement and project support letter were obtained, an extension of the site contract 
was pursued. 
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 Project site staff became engaged in this project through informal meetings during the 
pre-implementation phase. Each team member discussed their role with the project lead, asking 
questions, and providing implementation process suggestions. Three informal meetings were 
held so that all team members had the opportunity to discuss the project. The clinic staff were 
receptive to participation in the project and showed interest in the project by asking questions 
about the purpose and goals. Providers were interested in seeing how the project impacted 
comprehensive patient care due to information uncovered by the OTC medication survey. They 
also expressed uncertainty regarding how the additional assessment would affect their time with 
patients. In addressing this concern, several processes to monitor time management and 
workflow issues were considered, including monitoring check-in and check-out times, and 
delays in getting patients roomed. 
 Patient completion of the OTC medication survey and GerdQ tool was essential to project 
success. The CMA provided the tools to all patients meeting the project participant criteria as a 
part of the routine appointment check-in process. Patients were encouraged to complete the OTC 
medication survey to ensure a comprehensive medication record, and the GerdQ tool to improve 
upper GI symptom assessment and management.  
Implementation Process  
 The project implementation period was August 19, 2019, to December 3, 2019. 
Implementation began with a formal educational PowerPoint presentation (See Appendix N) 
during a Lunch-and-Learn session the week of August 19, 2019. The rationale and purpose of the 
project were discussed along with the expected impact the project would have on patient care. 
Training was also provided on evaluating the OTC medication survey and scoring the GerdQ 
tool. Providers received additional instruction on assessing BE risk and completing the post-visit 
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provider survey. Copies of the PowerPoint were given to all project team members to use as a 
reference. Additional copies were available for nurse practitioner students being precepted at the 
project site during the implementation period. Several sample GerdQ tools were used to practice 
the symptom and severity scoring to aid familiarity with the tool. Additional time was allotted 
for questions following the educational presentation. 
 Tool implementation began on Monday, August 26th, 2019. The project site was provided 
with 100 copies of the OTC medication survey listing GI medication categories, with the GerdQ 
tool in English on the back. The site received 25 copies of the full OTC medication survey with 
the Spanish GerdQ tool on the back. Additionally, 200 copies of the post-visit provider survey 
were divided among the providers’ offices. The CMA determined which patients met the criteria 
for tool completion, adding the tools to the routine appointment check-in forms to be completed 
by the patient. The CMA offered help in completing the forms and informed patients of their 
purpose if asked. Completed OTC medication surveys and GerdQ tools remained with the 
patient’s check-in paperwork for review by the provider. The GerdQ was scored by providers 
during the visit, and OTC medications were reconciled following the clinic policy. 
 During the office visit, providers conducted a BE risk assessment on any patient 
completing the GerdQ tool. The risk assessment was included at the end of the GerdQ and 
consisted of a list of the seven criteria for BE risk. The provider was instructed to circle any item 
that applied. Provider knowledge of GERD management and BE risk evaluation guided changes 
to the patient’s plan of care. The providers completed the post-visit survey following each new or 
annual follow-up visit. Incomplete OTC medication surveys and GerdQ tools were saved so that 
participation rates could be tracked. Completed post-visit surveys were stapled to the associated 
OTC medication survey/GerdQ tool. 
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 At the end of each clinic day, the site champion collected and secured the tools and post-
visit surveys in a folder in her office. The office manager and medical director monitored the 
project's impact on clinic workflow by observing for an increase in the average time between 
appointment check-in and check-out. Impact on clinic workflow determined whether additional 
OTC medication groups could be added to the OTC medication survey.  
 The project lead was available by telephone and e-mail throughout the project. All team 
members had contact information to reach the project lead with concerns regarding any part of 
the process. Weekly communication between the project lead and site champion was conducted 
to discuss successes and opportunities. A follow-up meeting was held with the project team on 
September 6, 2019, to address issues related to process integration, answer questions, adjust 
processes, and to review and compile data. The completed GerdQ tools were checked for scoring 
accuracy. The project lead returned to the clinic every two to three weeks thereafter to collect 
and record data and provide additional surveys and questionnaires as supplies ran low. 
 Successful implementation was defined by at least 80% completion of OTC medication 
surveys and GerdQ tools and by 90% completion of post-visit provider surveys. Accurate scoring 
of the GerdQ was essential in evaluating the presence and severity of GERD. Therefore, 100% 
accuracy was expected after the initial two weeks. Successful outcomes included identifying 
unreported OTC medication use and patients with a new diagnosis of GERD, improving GERD 
management, and identifying patients at high risk for BE who require screening.        
Plan Variation         
 This QI project had included plan variation at the outset to accommodate the needs of the 
project site. Concerns were raised during the pre-implementation phase that implementing the 
full OTC medication survey might impair clinic workflow because the volume of unreported 
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medications was unknown. The project was initiated using only the three GI categories in the 
OTC medication survey to address these concerns. Every two to three weeks, the workflow was 
reassessed. At week eight of implementation, the Pain/Headache OTC medication group was 
added. Because of time constraints related to practitioner training, no further OTC medication 
groups were added until week ten. The full OTC medication survey with eight medication 
categories was introduced for the final three weeks of the project. 
 The Plan Do Study Act (PDSA) cycle was used to identify process improvement needs 
throughout the project. The use of the PDSA cycle provided a method to fine-tune processes and 
address barriers to improvement. Several changes were made during the implementation period 
to improve data collection and aid in evaluating the GerdQ results and assess BE risk. Changes 
included providing GerdQ scoring instructions for each provider’s office, including the scoring 
scale for severity and impact on the GerdQ, and BE risk score for men and women on each of the 
tools. 
Summary 
        Implementation of this QI project was conducted in a small urban family practice clinic 
over 14 weeks in the Fall, 2019. Thoroughness during the pre-implementation phase and 
frequent contact with the project team created the foundation for successful implementation. The 
project team consisted of the entire clinic staff who provided suggestions on the implementation 
plan, which improved workflow during this phase. The implementation process began with the 
education of the team on the purpose, process, and evaluation tools. Ongoing reevaluation of the 
project occurred every two to three weeks. Frequent reassessment allowed the project team to 
identify factors impacting clinic workflow and accuracy of GerdQ and BE risk scoring so that 
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processes could be adjusted. This continuous process improvement allowed for successful 
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Chapter Six:  Evaluation of the Practice Change Initiative 
The intent of this chapter is to examine the effectiveness of the quality improvement (QI) 
initiative through evaluation of the outcomes data following implementation.  Evaluation helped 
to determine if project goals were met and provided a guide to sustainability. The primary 
objectives of this project included improving provider knowledge of patients’ over-the-counter 
(OTC) medication use, evaluating gastroesophageal reflux disease (GERD) symptoms and 
severity, and determining which patients are at high risk for development of Barrett’s esophagus 
(BE). 
Participant Demographics 
 This QI project was implemented in a privately-owned single-office family practice clinic 
located in urban north-central North Carolina. There were three medical providers in this clinic 
during the implementation period: the physician medical director and practice owner, a family 
nurse practitioner serving as site champion, and an adult-gerontology nurse practitioner who was 
being oriented to the position. The providers were responsible for reviewing the OTC medication 
survey and calculating the GerdQ score. Based on the survey review and GerdQ score, they then 
evaluated the BE risk in each patient. Following each encounter, a post-visit provider survey was 
completed noting the providers’ assessment of the information obtained.    
 During the 14-week implementation period, the OTC medication survey and GerdQ were 
provided to 82 adult patients who presented to the clinic to establish care or for an annual 
physical. Of these patients, 79 (96%) completed the surveys. Providers identified 25 (32%) of 
patients as having GERD based on their history and physical assessment versus 23 (29%) 
identified with GERD based on GerdQ scoring. Five patients (6%) with an indication for GERD 
based on their GerdQ score did not indicate self-treatment with OTC reflux medications. A 
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GerdQ severity score of eight or more indicates a diagnosis of GERD. The impact score is the 
sum of GerdQ questions five and six, with a score of two or higher indicating GERD.  
 Demographic information was collected on 62 (78%) of the 79 patient-completed forms. 
Of the 62 with demographic information, 25 (32%) were age 50 or older, 36 (58%) were male, 
and 26 (42%) were female. The majority of the patients were Caucasian (62%). The remaining 
38% were not identified by their individual race.  
Intended Outcomes 
 Three intended outcomes are addressed within the results of this QI project. The first 
intended outcome was to improve providers’ knowledge of OTC medication use and frequency 
among their patients. The OTC medication survey was utilized to evaluate this outcome. 
Secondly, identifying patients with GERD was necessary before addressing the third goal. This 
was accomplished through the use of the GerdQ tool. The final outcome was identifying patients 
at high risk for the development of BE. A BE risk assessment checkbox was included on the 
GerdQ tool. The long-term goal of this project was to establish a process to identify patients at 
high risk of BE. Screening the appropriate patients for this precancerous condition is an essential 
step in esophageal adenocarcinoma prevention. 
Findings 
            OTC medication survey. Of the 79 patients completing the OTC medication survey, 51 
(64%) reported taking at least one OTC medication monthly. During the first ten weeks of 
implementation, the survey included three gastrointestinal (GI) medication groups. Of the 61 
patients who completed the survey with three GI medication groups, 38 (63%) indicated using a 
GI OTC medication at least monthly.  
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          During week eight, a fourth OTC medication category was added to include OTC pain 
medications. Ten out of 79 patients completed the four-category survey. Beginning at week 11, 
the full OTC medication survey, including all eight categories, was introduced. Eight patients out 
of the 79 completed the eight-category survey from weeks 11 through 14.  
          In evaluating the heartburn/indigestion/reflux medication category, 29 (37%) of the 79 
patients responded to using OTC medications at least monthly, and 16 (20%) reported using 
them weekly or more often. Seven (10%) patients reported taking these medications at least 
daily. OTC pain medication use was also evaluated due to the impact on the GI system and the 
potential for drug-drug interactions. There were 18 surveys that included the OTC pain 
medication category with nine patients (50%) identifying at least monthly use. Five of the 18 
patients (28%) used OTC pain medication several times per month or more. Frequent OTC pain 
medication use, defined as at least weekly use, was reported by two patients (11%).   
          Post-visit provider surveys were completed for each of the 79 visits where patients 
completed the OTC medication surveys. Providers reported 18 (23%) of the 79 OTC surveys 
identified a new health problem to be addressed. Based on the OTC medication survey, providers 
reported same-day treatment plan changes during 20 (25%) visits. Treatment plan changes 
included new or altered medication regimens, tests, lifestyle modifications, and patient 
education. 
                GERD symptoms and severity. OTC medication used for self-treatment of reflux or 
heartburn was identified by 29 (37%) of the 79 patients (see Graph 1). Of the 29 patients using 
OTC heartburn medications, 13 (45%) used them monthly or several times per month. Weekly 
use or more often was indicated by 9 (31%) patients, and seven (24%) patients indicated the use 
of OTC heartburn medications at least daily. 
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Graph 1. Frequency of OTC reflux medication use (n=29) 
          When comparing the 13 patients reporting the use of OTC medication several times per 
month or less, 4 (31%) had GERD based on the GerdQ severity score. Of the 16 patients 
reporting weekly or greater OTC medication use, 14 (87%) had GERD based on the GerdQ 
severity score. Among the 29 patients indicating OTC reflux medication use at least monthly, 18 
(62%) could be diagnosed with GERD based on their GerdQ severity or impact score. Four 
patients (14%) were considered to have GERD based on the GerdQ impact score alone. Of these 
four patients, two had a GerdQ severity score of five, and two had a score of seven. All four 
patients meeting the GERD diagnostic criteria based on the GerdQ impact score indicated they 
took OTC reflux medications weekly or more to manage their symptoms. The mean GerdQ 
severity score was 8.55, and both the median and mode were 8. 
          Barrett’s esophagus risk.  BE risk was not evaluated on every patient completing the 
OTC medication survey and GerdQ tool. Providers included demographic information related to 
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BE risk factors on 62 (78%) of the 79 patient-completed forms (see Graph 2). In reviewing the 
demographic findings and BE risk factors, a diagnosis of GERD was associated with ten (28%)  
of the men and ten (38%) of the women. Caucasian race accounted for 32 (89%) men and 19 
(73%) women, and 14 (39%) of the men were smokers versus seven (27%) of the women. 
Patients 50 years or older comprised 36% (13) of the male group and 46% (12) of the female 
group. Waist-to-hip ratio (WHR), another indicator of BE risk, was seen in 8 (22%) men and 8 
(31%) women. Of the 62 patients, a family history of BE or esophageal cancer was noted in one 
man (3%) and one woman (4%). The male patient with a family history of BE or esophageal 
cancer was considered high risk for BE but had not yet reached age 50. The female also did not 
meet the criteria for BE screening. Aside from GERD, her only additional risk factor was 
Caucasian race. 
 
Graph 2. Individual risk factors for Barrett’s Esophagus by sex 
          Table 1 provides a summary, highlighted in yellow, of patients categorized as high risk for 
BE. High risk is defined in men with GERD having two or more additional risk factors, and in 
women with GERD having four or more additional risk factors. Of the ten men with GERD, 9 
(90%) were considered high risk for BE, with four (40%) who were age 50 or older. These four 
men met the screening criteria for BE during this QI project. Three were referred to 
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gastroenterology for evaluation. Of the ten women with GERD, none were considered high risk 
for BE. BE screening is not recommended for anyone less than age 50 years unless red flag 
symptoms such as dysphagia are present. Red flag symptoms were not identified in any of the 
patients completing the OTC survey or GerdQ. Based on the 79 post-visit provider surveys, five 
patients (6%) were identified as being high risk for BE. Nine (11%) were identified using the BE 
risk assessment box located on the GerdQ tool. 
                           Table 1. 
 
Summary 
          Findings from the QI project implementation provided valuable information that might not 
otherwise have been identified. The OTC survey tool identified that 64% of this clinic’s patients 
reported using OTC medications to self-treat. With this information, more focused evaluation of 
GERD using the GerdQ tool was possible. Patients self-treating GERD symptoms at least 
monthly comprised 36% of the respondents, and 46% of these respondents met the criteria for a 
diagnosis of GERD based on the GerdQ scores. Identifying patients with GERD, the primary risk 
factor for BE, is essential to determining BE risk. Nine patients were identified as high-risk for 
BE development, and four of these met the screening criteria of being 50 years or older. This 
multistep process is one measure that primary care clinics can use to offer holistic care and 
reduce risk for their patients. 
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Chapter Seven: Implications for Nursing Practice 
The DNP Essentials, a guide set out by the American Association of Colleges of Nursing 
(AACN, 2006), are the foundation upon which this practice doctorate rests. The eight 
components discussed in this chapter comprise the measured outcomes and competencies which 
each graduate must meet to be conferred the degree of Doctor of Nursing Practice (DNP). These 
essential components are encompassed within the DNP scholarly project. The process begins 
with the identification of a practice problem, moves through information synthesis, project 
development, and implementation, and culminates with the evaluation of the project outcomes. 
The project paper is the capstone of the DNP program and denotes the written evidence of the 
accomplishment of the DNP Essentials. 
Practice Implications 
 The eight DNP essentials provide a framework that informs evidence-based practice 
throughout this DNP project and future projects. The findings of this DNP project had several 
practice implications, including identification of patient self-medication practices and 
improvement in the identification of at-risk patients for Barrett’s esophagus (BE).  
             Essential I: Scientific underpinnings for practice. Scientific knowledge translation and 
application through nursing theory are at the core of this essential (AACN, 2006). Evidence and 
research from a wide range of sciences, along with nursing theory, frame and guide the 
development of evidence-based practice measures to improve practice and patient outcomes and 
quality of care (AACN, 2006). 
 This quality improvement (QI) project brought together the problem of an escalating 
incidence and mortality from esophageal adenocarcinoma (EAC), lack of screening guidelines 
for BE, and a lack of understanding of patient self-medication for gastroesophageal reflux 
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disease (GERD) to develop a clinic policy designed to improve identification of BE risk. There is 
disparity among gastroenterology organizations regarding BE screening. When coupled with a 
provider's lack of understanding of their patient’s GERD self-treatment, patients who are at risk 
for BE are overlooked, leading to identification only when alarm symptoms occur, possibly after 
esophageal adenocarcinoma (EAC) has developed. A review of the available literature identified 
reasons that patients omit disclosure of self-medication and measures to improve disclosure, such 
as structured interviewing during medication reconciliation (Sarzynski et al., 2014) and use of 
prompts (Jarrett, Cochran, Baus, & Delmar, 2019). Additional literature reviewed identified the 
GerdQ as a validated method to evaluate the presence and impact of GERD in primary care 
(Jones et al., 2009). The preceding information provided the foundation of this QI project with a 
goal of identifying patients at risk of developing BE who may need to be screened. 
 The ability to translate evidence and facilitate evidence-based practice change is the 
hallmark of the DNP-prepared nurse. Identification of practice and organization problems and 
their related concepts, and looking at issues from multiple perspectives are valuable skills when 
developing a practice change project. Visualization of concept relationships through concept 
mapping further defines the problem and suggests potential solutions. Evidence-based practice 
change is a complex, multidimensional process that is best guided using a framework based on 
sound theory. This project uses both the Iowa Model for Evidence-based Practice Change and 
Lewin’s Change Theory. Using a step-wise process, the Iowa Model guides the quality 
improvement process. When used in conjunction with Lewin’s Change Theory’s unfreezing, 
movement, and refreezing processes, implementation and integration will achieve greater 
success. 
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 Essential I provides the DNP-prepared nurse the ability to identify, evaluate, and translate 
available evidence into practice. Understanding nursing and change theories provide a solid 
foundation for the implementation and integration of practice improvement initiatives. When 
applied in conjunction with quality improvement models, healthcare practices and patient 
outcomes are improved. 
             Essential II: Organization and systems leadership for quality improvement and 
systems thinking. Essential II prepares the advanced practice nurse to develop practice 
improvement programs to improve quality and safety within the context of patient populations, 
organizations, and communities (AACN, 2006). Leadership involves the ability to clearly 
articulate ideas, incorporate financial planning and budgeting, evaluate health policy, and 
analyze risks and benefits (AACN, 2006). All of these skills are essential during project 
development.  
 This DNP project improved patient safety and care quality in several ways. Improved 
provider knowledge of patient over-the-counter (OTC) medication use has the potential to reduce 
drug-drug interactions and adverse reactions among their patient population. Additionally, 
provider knowledge of a patient’s diagnosis of GERD accompanied by identification of other BE 
risk factors will facilitate the optimization of treatment and referral for screening when 
appropriate, thus reducing morbidity and mortality. 
 In the pre-implementation phase of this QI project, a SWOT analysis was completed and 
a budget prepared. Potential weaknesses were identified and included increased provider 
workload and lack of EHR integration. Strengths included site champion and clinic staff interest, 
low cost to the practice, and acknowledgment of potential to improve quality of care. Open 
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channels of communication were maintained throughout the process through on-site meetings, 
telephone conversations, and electronic communication, including text messaging and e-mail.  
              Essential III: Clinical scholarship and analytical methods for EBP.  Scholarly 
activities in DNP education involve translation of evidence derived from research into clinical 
practice. Essential III requires analysis of existing and new research and applying it to solve 
practice, organization, or system problems to improve outcomes (AACN, 2006). Information 
technology is also essential in program and project development, analyzing data, and evaluating 
outcomes (AACN, 2006). 
 The literature review for this project found a practice gap in the identification of BE risk 
and also in screening recommendations. No nationally recognized standardized tool is available 
to measure BE risk, nor are the association guidelines clear on who should be screened. A 
practice barrier existed in identifying patients with GERD at this clinic as patients were not 
always forthcoming with their OTC medication use, and no standardized practice was in place to 
obtain this information. Additional literature was reviewed to determine evidence-based 
measures that could be employed to improve knowledge of OTC medication use, and validated 
tools to evaluate for the presence of GERD. Recommendations regarding BE risk assessment 
from several GI societies were analyzed to develop an evidence-based tool for determining who 
was at highest risk and would most benefit from screening. Synthesis of the available evidence 
initiated the development of an OTC medication survey, use of the GerdQ to diagnose and 
evaluate the severity and impact of GERD, and design of a BE risk assessment tool.  
 Analysis of data throughout the project timeframe and dissemination of project findings 
is vital to ongoing quality improvement and healthcare outcomes. The interim project findings 
were reviewed with the project site clinicians during several PDSA cycles, and revisions to the 
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project plan were made each cycle. Project findings were disseminated through a final report and 
presentation to the clinic staff, and by virtual podium presentation at the East Carolina University 
College of Nursing. Upon completion, the DNP scholarly project paper was uploaded to the 
ScholarShip, East Carolina University’s institutional repository of scholarly works.  
 Essential IV: Information systems/technology and patient care technology for the 
improvement and transformation of healthcare. The use of information technology to 
improve the quality of patient care and clinical outcomes is the basis for Essential IV. 
Proficiency in information systems, electronic health records (EHR), and data management tools 
is indispensable to the DNP-prepared nurse. The clinic EHR was used to identify baseline 
aggregate data about the clinic’s patient population, including the number of patients seen, payer 
sources, and general patient demographics. Microsoft® Office and Excel were used to compile 
and analyze, and display data using tables, charts, and graphs. Microsoft® PowerPoint was used 
to create an initial educational presentation for the project team and final poster displaying the 
data and project outcomes.  
             Essential V: Healthcare policy for advocacy in healthcare. Healthcare policy and 
advocacy are crucial to meeting the needs of patients, systems, and communities, no matter the 
size (AACN, 2006). The DNP nurse is prepared to meet these needs through policy and program 
development to reduce healthcare disparities, improve health, and prevent illness (AACN, 2006). 
The short-term goal of this project was to improve patient health and prevent illness by 
identifying OTC medication use, optimize treatment of GERD, reduce GERD impact on quality 
of life (QOL), and to improve risk assessment for BE. The long-term goal was to prevent the 
morbidity and mortality caused by EAC. Medication reconciliation in the primary care setting is 
a quality and safety metric set by both the Centers for Medicare and Medicaid Services (CMS) 
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and the Joint Commission (TJC). The short and long-term goals were met through the 
development of a clinic policy that advocated for improved medication reconciliation with the 
inclusion of frequently used OTC medications added to the EHR. Additionally, a strategy to 
evaluate GERD and its impact on QOL, along with BE risk assessment, allows clinicians to 
provide patient-centered recommendations for improvements in health and prevention of disease 
through disease management measures and screening. 
             Essential VI: Interprofessional collaboration for improving patient and population 
health outcomes.  The ability to both lead and collaborate are defining characteristics of the 
DNP-prepared advanced nursing practice. These characteristics occur within interdisciplinary 
teams across multiple healthcare settings and are essential in today’s complex healthcare 
environment (AACN, 2006). Teamwork among the site champion, project lead, project faculty, 
and clinic team was crucial in the development, implementation, and evaluation of this DNP QI 
project. Communication was effective among the entire project team and was carried out both in 
person and electronically. Effective communication, education, and collaboration facilitated team 
involvement and buy-in to the process and understanding of the changes in their day-to-day 
work. The site champion and clinic team were involved in interim project evaluation and process 
improvement throughout implementation. Collaboration with the site champion occurred during 
each PDSA cycle, and input was sought from affected team members when changes were made. 
Multimodal communication and frequent collaborative efforts facilitated teamwork and kept the 
QI project on course 
             Essential VII: Clinical prevention and population health for improving the nation’s 
health. Health promotion, risk reduction, and disease prevention are hallmarks of advanced 
practice nursing (AACN, 2006). Analysis of existing data identify GERD and BE incidence 
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increasing over the last four decades (Runge et al., 2015) with a corresponding seven-fold 
increase in EAC (Hang et al., 2018) which has an 18% five-year survival rate due, in part, to 
late-stage diagnosis (Peery et al., 2015). There are no established screening guidelines for BE, 
and gastroenterological societies have not come to a consensus on who is at highest risk for BE 
development, creating a gap in care. Additionally, GERD, the primary risk factor for the 
development of BE, often goes undiagnosed due to the ease of self-treatment with numerous 
OTC medications.  
 This project was designed to identify patient self-treatment of reflux symptoms, utilized a 
validated diagnostic tool for GERD, and provided a BE risk assessment tool for providers to 
prompt appropriate screening for BE. Patients with new or undertreated GERD have improved 
QOL when their GERD symptoms are effectively managed, along with a reduction of risk of 
developing BE (Gikas and Triantafillidis, 2014). The results of this QI project found that 
education of providers on BE risk factors and the use of a simple risk factor assessment tool 
improved identification of patients who require risk factor modification and screening. In the 
future, BE risk assessment should be conducted on any patient with a diagnosis of GERD at the 
time of referral for colorectal cancer screening or surveillance so that concurrent BE screening 
can be completed if indicated.  
             Essential VIII: Advanced nursing practice. Essential VIII encompasses advanced 
assessment and clinical judgment, and development of interventions and processes through 
analysis and synthesis of research to accomplish evidence-based care and improved quality and 
outcomes (AACN, 2006). Therapeutic relationships, leadership, and collaborative practice are 
utilized to educate, mentor, and guide individuals and teams to facilitate the quality improvement 
of complex problems (AACN, 2006). 
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 Analysis and synthesis of the current literature provided the basis for conceptualization of 
a process to identify patients at high risk for development of BE by first determining who is self-
treating reflux symptoms and then using the GerdQ tool to diagnose GERD and its severity and 
impact on QOL. Implementation of this process involved building and leading an 
interprofessional team to close a gap in care through OTC medication reconciliation in this small 
urban primary care clinic. Educational and assessment tools guided the clinicians’ evaluation and 
decisions regarding the need for treatment modification and BE screening.  
Summary  
                The AACN’s DNP Essentials are the foundation of the advanced practice nurse’s 
education, guiding scholarly work to improve healthcare for individuals, systems, and 
communities. Analysis and synthesis of research lead to the development of new evidence-based 
methods to improve quality and safety in healthcare. The use of information systems and 
technology is essential for tracking and analyzing data and provide a means for rapid 
reevaluation and revision of project plans. Interprofessional collaboration, communication, and 
teamwork are crucial for managing complex healthcare problems. A sound understanding of 
each of the DNP Essentials allows DNP-prepared nurses to translate evidence into practice, to 
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Chapter Eight: Final Conclusions 
The intent of this DNP quality improvement (QI) project was to improve the 
identification of patients at increased risk for development of Barrett’s esophagus (BE) in an 
urban family practice in N.C. The implementation of the OTC medication survey and GerdQ, 
along with provider-identified BE risk factors, was effective in identifying at-risk patients among 
the 79 patient respondents. This chapter will review the significance, strengths, and limitations of 
this QI project, and practice recommendations will be discussed  
Significance of Findings  
           There were several clinically significant findings identified as a result of this QI project. 
The over-the-counter (OTC) medication survey showed monthly or greater OTC medication use 
in 64% of the patients completing the survey. This led provider identification of a new clinical 
problem to be addressed in 23% of respondents and a change in the treatment plan in 25% of 
respondents. The data obtained from this small group of patients serves to identify potential gaps 
in care caused by previously unknown OTC medication use.  
          The stated purpose of this QI project was to increase the identification of patients at risk 
for BE and to prevent esophageal adenocarcinoma (EAC). Identification of BE risk must first 
start with assessing its primary risk factor, GERD.  In evaluating the responses to the OTC 
medication survey, 32% of the 79 patients identified using OTC medications to treat their reflux 
symptoms at least monthly, and 62% of these patients were diagnosed with GERD. Based on this 
information along with additional BE risk factors, 11% were found to be at high risk, with 5% 
meeting the criteria for a screening endoscopy. These findings suggest that the tools selected, 
when used together, are effective in identifying patients who are at risk in the primary care 
setting.                 
IDENTIFYING BARRETT’S ESOPHAGUS RISK                                                                   70 
 Project Strengths and Weaknesses 
          Several strengths were identified, among them were provider and staff buy-in and interest 
in process improvement to improve holistic patient care. Because all project partners had a stake 
in the process, interprofessional collaboration was enhanced. This allowed improved 
understanding and buy-in of the project and process, aiding in effective communication when 
project changes were required. The use of patient-completed tools reduced the amount of time 
staff spent collecting needed information. The GerdQ tool was selected for its simplicity of use 
and high specificity for GERD. Instruction on the project, written guidance on the use of tools, 
and frequent contact with the on-site QI project team assisted in keeping everyone involved 
during the 14-week implementation period. 
          The project was not without its weaknesses. Providers were responsible for reconciling 
each patients’ medication list leading to increased appointment time spent documenting. The 
appointments available for inclusion during the project were limited due to the AGNP provider 
being in training, which limited her participation. The GerdQ and BE risk tools required revision 
several times to improve scoring and score assessment, which led to several missed opportunities 
for GERD treatment optimization. The inability to integrate any of the project steps 
electronically, or to easily extract information from the EHR was a barrier as well.  
Project Limitations 
          The number of patients included in the QI project was limited to patients new to the 
practice or presenting for annual physicals, therefore, limiting the identification of the scope of 
the problems being addressed. Because the number of ancillary office staff was limited at this 
practice, providers were responsible for the increased paperwork required to complete the QI 
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project process. Delayed introduction of the full OTC medication survey limited the ability to 
determine the full scope of OTC medication use among the patients who completed the surveys.  
Project Benefits 
          This project provided several benefits to this family practice allowing them to provide 
more comprehensive care for their patients. Providers gained an understanding of the scope of 
OTC medication use among a portion of their patient population. This knowledge prompted 
immediate changes to treatment plans and identified new health issues that needed to be 
addressed. The long-term outcome is that patient care will be more holistic as providers become 
fully informed about the measures patients are using to manage their health issues on their own.  
          One of the challenges of decreasing rates of EAC is identifying methods for screening 
those at highest risk for the development of BE, its precursor lesion. This QI project identified 
one successful method that could be employed in any practice to guide BE risk assessment. Early 
screening and identification of BE carries the added benefit of reducing the estimated $184,000-
$250,000 costs associated with a diagnosis of EAC (Mariotto, Yabroff, Shao, Feuer, & Brown, 
2011). The use of a validated tool, the GerdQ, to determine the presence or undertreatment of 
GERD and then identifying additional risk factors for BE led to the optimization of GERD 
treatment and referral for BE screening in several patients. Appropriate screening of at-risk 
patients improves the odds of detecting BE and early EAC, preventing long-term consequences, 
increased cost burden, and high mortality of late-stage esophageal cancer. These interventions 
served to meet the Institute for Healthcare Improvement’s Triple Aim objectives of improved 
per-capita costs, experience of care, and population health (2020).   
 
 
IDENTIFYING BARRETT’S ESOPHAGUS RISK                                                                   72 
Practice Recommendations 
          Based on QI project findings, several practice recommendations should be considered. The 
use of the full OTC medication survey should continue. The information obtained from the OTC 
medication survey is useful beyond the scope of this project, providing to an opportunity to 
identify OTC medication misuse, drug-drug and drug-disease interactions, and previously 
unknown health concerns.  
          One recommendation is to incorporate measures that would streamline the information-
gathering process. Patients should receive pre-appointment forms by mail or online for 
completion at home to improve the accuracy of the OTC medication survey. The integration of 
these forms in the electronic health record through the patient portal prior to each visit may 
provide a way to streamline the process and allow for provider review during pre-visit planning. 
          Use of the GerdQ and BE risk tools as a standardized assessment should continue for any 
patient with a diagnosis of GERD and anyone using OTC reflux medications monthly or more 
often. Early management of GERD and improving modifiable risk factors will reduce patients’ 
risk of developing BE. Patients referred for a colonoscopy at age 50 or older should be evaluated 
for BE risk at the time of referral as a standard protocol. Those who are identified as high-risk 
should be referred for a screening esophagoscopy along with the colonoscopy. Finally, patients 
not meeting BE screening criteria but who have a family history of esophageal carcinoma or BE 
should be evaluated. Assessment should include the degree of relationship and age at the time of 
diagnosis, and referral to GI may be warranted based on the provider’s clinical judgment.  
Final Summary 
          The prevalence of Barrett’s esophagus and esophageal adenocarcinoma is increasing in the 
U.S. at an alarming rate. With a five-year survival rate of 18% for EAC and no national 
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standardized guidelines for screening for BE, it is up to the primary care practitioner to evaluate 
disease risk and determine the appropriate recommendations. This evaluation is made more 
difficult due to patient self-treatment of GERD symptoms with OTC medications leaving the 
provider unaware of the potential risk. With the introduction of an OTC medication survey, a 
validated GERD evaluation tool, and BE risk factor checklist, this QI project demonstrated an 
effective way for the practitioner to evaluate a patient’s risk and develop an appropriate 
treatment plan to ameliorate the risk or send for a referral. Ongoing utilization of these tools and 
implementing a BE screening protocol are essential steps in improving holistic care and reducing 
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Article                        











Albert, S. M., Bix, 
L., Bridgeman, M. 
M., Carstensen, L. 
L., Dyer-
Chamberlain, M., 
Nefesh, P. J., & 
Wolf, M. S. 
(2014). Promoting 
safe and effective 








VII Summit meeting 




and CHPA to 
promote 
safe/effective use 
of OTC meds by  
looking at the way 
these meds are 
used especially by 
older adults 
Panel looked at 
health literacy, 
decision making, 





use; found that 
younger pt. more 
likely to get 
advice from 
friends/family; 
older adults from 
pharmacist or 
provider; 
clinicians need to 
ask questions 
about OTC med 
use to address 
issues and 
misperceptions 




learn about OTC 
behaviors and get 





need to be 
addressed and 
areas for further 
research by 
looking at what 
is known and 
where there are 























information on the 
DNP Essentials  
Details the eight 
required 
essentials 





Used in chapter 

















VII Background on 





function of NP. 
General 
background on 
NP purpose and 




Bolier, E. A., 
Kessing, B. F., 
Smout, A. J., & 












I Systematic review 














some fit more 
than 1: Generic - 
3; esophageal 
GERD symptoms 
- 33; extra-esoph 
symptoms - 3; 
response to 
treatment - 14; 
diagnosis - 7; 
quality of life - 
18; 
infants/children - 
8; others - 6. No 
single 
questionnaire 
useful to measure 




of GERD in 
clinic setting. 2 
questionnaires 
identified as 
applicable to the 
project: GerdQ 
and RDQ, both 
validated and 







be helpful here, 
but review 
provided enough 
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information to 
r/o tools that 
would not be 





















and value; also 
includes 
regulatory info, 






statistics on OTC 
medication use 
and perceived 
benefits; it is a 
trade association 
website so there 
is bias 
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Crews, N. R., 
Johnson, M. L., 
Schleck, C. D., 
Enders, F. T., 
Wongkeesong, L., 
Wang, K. K., . . 













II Randomized trial 
looking at clinical 
risk and predictors 
of BE found male 
sex, and central 











presence of GERD 
BE risks are well-
defined and 
cumulative with 
odds of EE or BE 
3.7 x higher with 
3-4 risk factors, 
and 5.7 x higher 
with 5+ risk 




factors, age > 50, 
GERD, 
Caucasian race, 
smoking, and fam 
history also 
increase risk; 
ETOH use not a 
risk. 
Most screening 
for BE focuses 
on presence of 
GERD but in this 
study prevalence 
of EE was 
similar between 
those with and 
w/o GERD 
although those w 
symptoms had 










age 50 or older 
and 98% 
Caucasian both 
known as risks 
for BE but limits 
application of 
results to other 
racial groups. 
Cullen, L., & 
Sigma Theta Tau 
International. 
(2017). Evidence-




and tips from the 




Sigma Theta Tau 
International. 
V Book discussing 
all aspects of 
implementation of 
evidence-based 
practice using the 
Iowa Model for 
Evidence- based 
Practice Change 










of practice change 
using this model. 
Will refer back 
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Gikas, A., & 
Triantafillidis, J. 
K. (2014). The 
role of primary 
care physicians in 
early diagnosis 





Journal of General 
Medicine, 7, 159. 
doi:10.2147/IJGM.
S58888 
VI Discusses the role 
of PCPs to 
diagnose and 
manage chronic GI 
diseases. 
Discussion of the 
role of GI cancer 
screening; the 
burden of disease 




















s which differ 
from ACG and 






regimen, use of 
PRO tools to 
eval 
effectiveness 
Grusell, E. N., 
Mjörnheim, A., 
Finizia, C., Ruth, 
M., & Bergquist, 
H. (2018). The 
diagnostic value of 












IV Cohort study 
design used to 
determine the 
value of using the 
GerdQ when 
atypical symptoms 
of GERD are 
present; when 
atypical symptoms 
are the main 
presenting signs of 
GERD sensitivity 
is low(36%) and 












score was 8 or 
higher for dx 
GERD. Use of 
the GerdQ with 
atypical 
symptoms might 
have value in 





















provider to send 
for endoscopy. 
Strengths include 
the size of the 
study (n=646) 
and tested pt. 
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Gyawali, C. P., 
Kahrilas, P. J., 
Savarino, E., 
Zerbib, F., Mion, 
F., Smout, A. J., . . 
. Roman, S. 
(2018). Modern 
diagnosis of 





I Discussion of 
prevalence and 
impact of GERD 
and modern 







such as the 
GERDQ , and PPI 







GERD in primary 
care, but are not as 
sensitive or 
specific as 
ambulatory pH and 
impedance testing 








biopsy should be 
considered in PPI 
non-responders or 
















primary care is 





PPIs. Use of a 
validated GERD 
questionnaire is 
helpful in the 
initial diagnosis 

















for testing and 
confirmatory 
diagnosis. Lack 
of access to 
specialty care is 
a barrier for 
confirmatory 
diagnosis. 
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Hang, T. P., 
Spiritos, Z., 
Gamboa, A., 
Chen, Z., Force, 

















VI Descriptive study 




and other epithelial 
cancers looking at 





1973 and 2014 
finding a change 
in incidence of 
733% during that 
time period with 
an average annual 
percent change of 
5.4%. The annual 
percent increase 
plateaued during 





of early stage 





related to EAC 
showing a seven-
fold increase in 
incidence over 
the past four 
decades. 
Additionally, 
only 21% of 
patients are 
















VII Background on 
organization 
readiness for 









when planning a 
QI project. Part of 
the HRSA's QI 
Toolbox. 
Used in paper to 









of the value of 
QI, and the 
ability to 
collaborate. 
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Holt, K. M., & 





process in an 
internal medicine 






VI Implementation of 
a med 
reconciliation 
process to be 
completed by 
nurses and MA's 
by reviewing med 











still on list, 
changed meds 













bringing all meds 
in; using only 1 
pharmacy, 
knowledge of all 
meds taken 
Obtaining 












result, but likely 
not sustainable; 
did not break 




24% of records); 
Based on TJC pt. 
















VII Overview of the 












as screening for 























VI Study of the 
revised Iowa 
Model to evaluate 
and validate for 





were identified by 
users and then 
once rewritten 
was evaluated 
and validated by 
participants of the 
22nd National 
EBP Conference.  
Updated changes 
for EBP practice 
change in current 
healthcare 
environment. 




Ireland, C. J., 
Laws, T. A., 
Gordon, A. L., 
Thompson, S. K., 
& Esterman, A. 
(2018). General 
practitioners’ use 
of risk prediction 







Care and General 




practitioners and a 
GI provider to 
evaluate use of 
risk prediction 






time poverty, tool 
format, relevance, 
remembering to 













for use in clinical 
practice. When 
evaluating the 
use of any tool 




Iyer, P. G., & 












survival rate trends 
Evaluation and 
treatment 
methods for BE 
and EAC are 
improving but 
identifying 
patients at risk 
who should be 
screened remains 




to be little 
agreement among 




continue to be a 
barrier for 
screening for BE 
and this limits 
the improvement 
in EAC survival 
rates. 
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GI societies on 
what factors 
constitute high 




Cochran, J., Baus, 
A., & Delmar, K. 
(2019). 
MedManage: The 
development of a 
tool to assist 
medication 
reconciliation in a 
rural primary care 









developed in rural 
primary care clinic 
to help improve 
medication 
reconciliation in 
high risk patients; 
Use of tool 
increased OTC 
reporting by 82%, 
PRN reporting by 
3%, and herbals 
and supplements 
by 28% 
Tool consists of 
body diagram and 
symptom prompts 
asking pt. to list 
meds taken for 
that symptom 
over past 2 
weeks. Also asks 
pt. to list herbals, 
supplements, skin 
care products, and 
dietary 
supplements 





some pts reluctant 
to provide info on 
OTC use 
Pictures used to 
help low-literacy 
pts, but still had 
trouble 
completing the 
form. Useful as a 
prompt for 








help pt. recall 
OTC medication 
use. 
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Jones, R., 
Junghard, O., 
Dent, J., Vakil, N., 
Halling, K., 
Wernersson, B., & 
Lind, T. (2009). 
Development of 
the GerdQ, a tool 













IV Development of 
the GerdQ, a 
patient-centered 
self-assessment 
tool for diagnosis 
and management 
of GERD with 
validation studies. 
Seminal work for 
this tool. 
GerdQ tool found 
to be sensitive at 
65% and specific 
at 71% for 
GERD; high 
enough validity 

















is 6 questions, 
easy to use, can 





the owner of this 
tool.  











VI Background of 



















Kuipers, E. J., & 
Spaander, M. C. 
(2018). Natural 













BE is more 
common than 
thought but risk 
of progression is 
low. Still no gold 
standard for risk 
prediction but 
models are being 




within the past 5-
10 years to 
discuss GERD 
and association 




EAC; good for 
additional 
background 
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Levy, A. G., 
Scherer, A. M., 
Zikmund-Fisher, 
B. J., Larkin, K., 
Barnes, G. D., & 
Fagerlin, A. 
(2018). Prevalence 


























fear of judgement 




important to care; 
concern about 
time constraints; 
not wanting info 
in EHR; not 










that 81% and 





providers need to 






L., Metcalf, J. A., 
Paolini, C. A., 
Napier, A. H., 
Coogle, C. L., & 


















V Review of three 
EBP change 





Focus of the 
review is the use 
of Lewin's 
Change model for 
the translation of 
research into 
practice. Reviews 












ways in which to 
incorporate 
Lewin into EBP 
and how each 
project managed 
the 3 steps of 
practice change. 
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Mariotto, A. B, 
Yabroff, K. R., 
Shao, Y., Feuer, E. 
J., & Brown, M. L. 
(2011). Projections 
of the cost of 
cancer care in the 
United States: 
2010–2020. 






VI Uses SEER data to 
project the cost 
from 2010-2020 of 
the 17 most 
prevalent cancers 
in the U.S.  












156,000 for the 
final year of life 
with cost 
dependent on age 
at diagnosis. 
The per 
diagnosis cost of 
esophageal 
cancer is more 
than $250 
thousand for the 
first and last year 
of life combined 
if under 65 years 
of age, and $184 
thousand if 
diagnosed at age 
65 or older. 
McCarthy, L., Su, 
X., Crown, N., 
Turple, J., Brown, 
T. E. R., Walsh, 


















studies looking at 
med reconciliation 















med list review in 
some 
combination; 
history most often 














feasible in most 
ambulatory care 
settings. Lack of 
info in any study 
on effectiveness 
of accuracy of 






and accuracy of 
list; for purposes 
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practice in nursing 
& healthcare: A 




V Guideline that 
provides 
information on 
























VII NCI looks at 
cancer trends and 
cost burden for 
cancers and lists 
aggregate costs of 
top 17 cancers in 
US. 
Esophageal 
cancer the US 







more than $1.3 
billion in 2010 to 
nearly $1.7 
billion in 2018. 
Aggregate costs 
are separated by 
phase: $683 




ongoing care, and 
$791 million in 
the last year of 
life.  
Based on the 
2018 data, the 
overall annual 
cost of care for 




$1.7 billion. The 
annual cost can 
be broken down 
into phases of 
care with $683 
million spent on 
initial care, $204 
million for 
ongoing care, 
and $791 million 
for care during 
the last year of 
life. If early 
screening 
improves, these 
costs could be 
substantially 
reduced.  
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Noone, J., & 
Blanchette, C. M. 









VI Targeted review of 
lit to determine 
economic value of 
self-care measured 
in access, time, 
productivity 






value to pts, 
payers, employers 














choice among all 
adults; pt. feel 
that self-care is 





















Peery, A. F., 
Crockett, S. D., 
Barritt, A. S., 
Dellon, E. S., 
Eluri, S., 
Gangarosa, L. M., 
. . .Sandler, R. S. 









VI Report on burden 
of GI disease in 
the US looking at 
incidence and 
prevalence, costs 
to evaluate and 




cancer rates and 
















report completed  
by the American 
Gastroenterologi
cal Association 
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10.1053/j.gastro.2
015.08.045 
Peery, A. F., 
Crockett, S. D., 
Murphy, C. C., 
Lund, J. L., 
Dellon, E. S., 
Williams, J. L., . . . 
Sandler, R. S. 
(2019). Burden 
and cost of 
gastrointestinal, 
liver, and 
pancreatic diseases  








VI Review of burden 
and cost of GI 
disease in the US. 
This is an update 
to the 2015 report. 
Noted data 
changes related to 
incidence of 
esophageal cancer 




now derived from 
CDC. 
Updated project 
to reflect most 
current data on 
esophageal 
disease compiled 
by the AGA 
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Rey, E., Barceló, 
M., Zapardiel, J., 
Sobreviela, E., 
Muñoz, M., & 
Díaz-Rubio, M. 
















and specificity for 




63.2/80.2%  and 
for PPI users with 
ongoing symptoms 
sens/spec was 
65.4/71.8% using a 
cut-off score of 3 
Study looking at 
the validity of 
RDQ GERD tool 
to ID GERD 
based on the 
Montreal 
definition of 




was useful for 
those on and off 
PPIs; would be 
useful in primary 
care to establish a 
diagnosis of 
GERD by the 
Montreal def of 
troublesome 
symptoms.  
RDQ is a 12 
question tool, 
harder to find for 
use in QI project 














hour pH testing 
although other 
studies have 
validated in this 
manner. 
Richter, J. E., & 

























GERD related to 
background of 
the problem 
Rubenstein, J. H. 
& Thrift, A. P. 
(2015). Risk 
factors and 









VI Looks at 
individual and 
population risks 
for BE and 
compares the 
current models for 
BE risk assessment 
No gold standard 
tool identified to 
assess risk for BE 
but dose note that 
the risk 
assessment tools 
used for BE 
perform better 









tools for BE; 
good background 
information on 
BE risk in 
populations 




Runge, T. M., 
Abrams, J. A., & 








Clinics of North 
America, 44(2), 
203. 
VI Overview of 
epidemiology of 
BE and EAC; 
breaks down odds 
of BE with 
individual risk 
factors; also looks 
at progression to 
EAC factors and 




risk factors and 
odds ratios for 
each  
 Used to discuss 
risk factors of 
progression and 




for BE in clinic 
Sarzynski, E. M., 
Luz, C. C., Rios-
Bedoya, C. F., & 
Zhou, S. (2014). 
Considerations for 
using the 'brown 





Quality in Primary 
Care, 22(4), 177. 
VI Cross-sectional 
pilot study; 
conducted in a 







72% brought in 
medications and 
only 39% brought 
all meds. Only 
35% med lists 
were complete; 
only 6.5% were 
accurate. Best 




but was useful 
with both groups 
Limitations: 
small study in 
singe office over 
3-month period. 
Study found that 
OTC med 
documentation 





info on meds 
used among both 
groups. 
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Serper, M., 
McCarthy, D. M., 
Patzer, R. E., 
King, J. P., Bailey, 
S. C., Smith, S. G., 
















conducted in 2 
settings (academic 
medical center and 















of their entire 
medication 
regimen including 




knows of all 
meds; 84/86% 
think they know 
about OTCs; 
95/85% think 




































quality of care.   
Shaheen, N. J., 
Falk, G. W., Iyer, 
P. G., Gerson, L. 















I Clinical practice 
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Spechler, S. J., 
Sharma, P., Souza, 
R. F., Inadomi, J. 

















I Position statement 
and practice 










treatment of BE 
Used to compare 
with guidelines 











Uhl, M. C., 
Muth, C., Gerlach, 
F. M., Schoch, G., 
& Müller, B. S. 
(2018). Patient-
perceived barriers 




review in primary 








VI Qualitative study 
of 31 pts to 
determine barriers 
and facilitators to 
implementation of 
med reconciliation 






be necessary for 












wanting to justify 
OTC med use; 






med list can 
provide better 
understanding of 
how to overcome 
them. Study 
conducted in 
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VI Exemplar of use of 















Use as an 
exemplar on use 









Wolff, C. M., 
Nowacki, A. S., 
Yeh, J., & 
Hickner, J. M. 
(2014). A 
randomized 





Journal of the 









pt. reviews and 
updates printed 

















rec added approx. 




group was in the 
both interventions 
group with 75.6% 
agreement in med 
list; multistep 









adults 18+ so not 
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Zabaleta-del-




Llobera, J., Bellón, 























primary care and 















directed at health 
promotion/diseas
e prevention at 
once; conclude 
that higher risk of 
the population 
and intensity of 
the intervention, 
the more effective 
it is 



























Incomplete medication record 
Missed opportunities to reduce 
risk and screen for disease 
Potental for medication 
interactions and adverse 
events 
Barrier to comprehensive care 
Risk Assessment 
1. Treatment optimization 
2. Appropriate screening 
3. Improved patient satisfaction  
4. Reduced healthcare costs 
5. Comprehensive Care 
Complete medication record 
Knowledge of patient self-care 
practices 
Opportunity reduce drug 
interactions and adverse events 








“I can manage this on my own.” 
“This information isn’t important.” 
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Appendix C 
Iowa Model Revised 
 
(Iowa Model Collaborative, 2017).  
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until process and 
behavior is    
established 
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Appendix E 
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Item Cost Quantity Total
Supplies
      Staples 20 lb. copy paper - 8-ream case 37.45$       1 37.45$          
      HP Black toner cartridge for HP LaserJet Pro 166.92$     1 166.92$        
Lunch and Learn
      Assorted Sandwich Tray 45.00$       1 45.00$          
      Large Salad 15.00$       1 15.00$          
      Tea - 1 Gallon 5.00$         2 10.00$          
Two Week Follow-up Breakfast Meeting 
      Bagels and Muffins 30.00$       1 30.00$          
      Coffee 15.00$       1 15.00$          
Wrap-up/Results Lunch Meeting
      Assorted Wraps 35.00$       1 35.00$          
      Large Salad 15.00$       1 15.00$          
      Cookie Tray 15.00$       1 15.00$          
      Tea - 1 Gallon 5.00$         2 10.00$          
Travel - Round Trip $0.58/mile (as of Jan. 1, 2019)
       64 miles/trip 37.12$       10 371.20$        
765.57$      
Barrett's Esophagus Risk Project Budget
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QI Project Self-certification Tool 
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Appendix H 
DNP Project Post-visit Survey and Data Collection Tool 
 
Provider Post-visit Survey 
1. Based on the OTC medication survey did you identify a new problem to be addressed now or at a future visit? 
 Yes No 
2. Based on the OTC medication survey did you make a change to the treatment plan: education, medication, 
testing, other treatment, referral? 
 Yes No 
3. Based on the GerdQ results did you identify previously unknown or under-treated GERD? 
 Yes  No 
4. Is this patient at increased risk for Barrett’s esophagus based on the BE risk assessment?  
Yes No 
5. If at risk for BE, based on your clinical assessment, how do you plan to manage? Circle all that apply. 
Monitor/Continue Current Regimen    Lifestyle Mods     Optimize GERD meds     Refer to GI     Refer for EGD 
 
Data Collection Tool 
 
BE Risk QI Project Data Collection Tool
# GerdQ # New # BE Q5 Q5 Q5 GERD, male,
# Pts/ # Forms Completed GERD Dx High Risk Q1 Yes Q2 Yes Q3 Yes Q4 Yes No Change Modify Tx Referral  2 other RF
Week 1 Project Educational Seminar
Week 2 Started data collection
Week 3 14 13 0 0 1 3 0 0
Week 4
Week 5
Week 6 17 16 3 1 5 5 3 1 1 2
Week 7
Week 8 9 8 4 1 2 3 4 1 2 1
Week 9
Week 10 16 16 4 2 4 4 4 2 2 3
Week 11
Week 12 15 15 3 1 4 3 3 1 1 1 2
Week 13
Week 14
Week 15 11 11 2 0 2 2 2 2 1 1
82 79 16 5 18 20 16 7 4 4 9
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Appendix I 
Over-the-counter Medication Survey 
 
List over-the-counter medications taken since your last visit. Circle how often you take them. 1 
1. Pain/headache (include oral and topical medicines):  2 
Name/Dose________________________________________________________________________ 3 
 4 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 5 
 6 
2. Cough/Cold:  7 
Name/Dose________________________________________________________________________ 8 
 9 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 10 
 11 
3. Sinus/Allergies (include nasal sprays, inhalers, and oral medicines):  12 
Name/Dose________________________________________________________________________ 13 
 14 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 15 
 16 
4. Sleep aids:  17 
Name/Dose________________________________________________________________________ 18 
 19 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 20 
 21 
5. Topical Ointment/Cream/Lotion/Shampoo/Eye or Ear Drops 22 
 Name/Dose________________________________________________________________________ 23 
 24 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 25 
 26 
6. Diarrhea/Constipation (include suppositories, enemas, and oral medicines):  27 
Name/Dose________________________________________________________________________ 28 
 29 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 30 
 31 
7. Gas/Bloating: 32 
Name/Dose_________________________________________________________________ 33 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 34 
 35 
8. Heartburn/Indigestion/Reflux: ***** 36 
Name/Dose________________________________________________________________________ 37 
 38 
Never/Rarely-----Monthly---------Several times/month------Weekly-------Several times/week-------Daily or more often 39 
 40 
 41 
*****Please complete the GerdQ assessment on the back of this page if you take any over the counter or 42 
prescription medications for heartburn, indigestion, or reflux symptoms. 43 
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Appendix J 
AstraZeneca License Agreement for the GerdQ Tool 
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Appendix K 
GerdQ Tool – English 
 
       Total Score______/ Impact Score______ 
                                                                                                            8+                                2+ 
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Appendix L 
GerdQ Tool – Spanish 
 
       Total Score______/ Impact Score______ 
                                                                                                          (8+)                              (2+)   
                 
BE High Risk 
Male 
GERD + 2 
Female 
GERD + 4 
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Appendix M 
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Appendix N 
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